Oxidative Stress in Antigen Processing and Presentation

Abstract

Antigen processing and presentation are fundamental for connecting innate and adaptive immune responses in combating cancers and infections. Reactive oxygen species (ROS), serving as second messengers in various physiological processes, play a vital role in modulating antigen processing and presentation. However, oxidative stress due to an imbalance characterized by excessive accumulation of ROS or inadequate antioxidant defenses can severely impair antigen-specific immune responses, contributing to the pathophysiology of multiple health conditions, notably including various cancers, cancer-associated infections and autoimmune diseases. This review comprehensively investigates the multifaceted effects of ROS on antigen processing and presentation, encompassing immunopeptide generation, the functionality of antigen-presentation machinery (APM), and the interactions of antigen-presenting cells and antigen-specific effector cells. It emphasizes the critical pathophysiological roles of oxidative stress in diseases such as cancers, cancer-associated infections and autoimmune diseases. Moreover, we delve into the therapeutic potential of targeting redox homeostasis to enhance antitumor immune responses. By illuminating the intricate interplay between ROS and immune functionality, this review provides an essential theoretical framework for developing innovative immunotherapy strategies aimed at restoring immune competency and improving clinical outcomes in patients with immune-related diseases.

Keywords

antigen processing and presentation / antioxidant / immunotherapy / oxidative stress / reactive oxygen species (ROS)

References

[1] H. Gaillard, T. García-Muse, and A. Aguilera, “Replication Stress and Cancer,” Nature Reviews Cancer 15, no. 5 (2015): 276–289.

[2] M. Jiang, K. Jia, L. Wang, et al., “Alterations of DNA Damage Response Pathway: Biomarker and Therapeutic Strategy for Cancer Immunotherapy,” Acta Pharmaceutica Sinica B 11, no. 10 (2021): 2983–2994.

[3] Z. Zhang, M. Lu, Y. Qin, et al., “Neoantigen: A New Breakthrough in Tumor Immunotherapy,” Frontiers in Immunology 12 (2021): 672356.

[4] S. Jhunjhunwala, C. Hammer, and L. Delamarre, “Antigen Presentation in Cancer: Insights Into Tumour Immunogenicity and Immune Evasion,” Nature Reviews Cancer 21, no. 5 (2021): 298–312.

[5] E. Reeves and E. James, “Antigen Processing and Immune Regulation in the Response to Tumours,” Immunology 150, no. 1 (2017): 16–24.

[6] K. Yang, A. Halima, and T. A. Chan, “Antigen Presentation in Cancer—Mechanisms and Clinical Implications for Immunotherapy,” Nature Reviews Clinical Oncology 20, no. 9 (2023): 604–623.

[7] Q. Kang and C. Yang, “Oxidative Stress and Diabetic Retinopathy: Molecular Mechanisms, Pathogenetic Role and Therapeutic Implications,” Redox Biology 37 (2020): 101799.

[8] A. van der Pol, W. H. van Gilst, A. A. Voors, and P. van der Meer, “Treating Oxidative Stress in Heart Failure: Past, Present and Future,” European Journal of Heart Failure 21, no. 4 (2019): 425–435.

[9] Y. Herdiana, S. Sriwidodo, F. F. Sofian, G. Wilar, and A. Diantini, “Nanoparticle-Based Antioxidants in Stress Signaling and Programmed Cell Death in Breast Cancer Treatment,” Molecules 28, no. 14 (2023): 5305.

[10] W. Dröge, “Free Radicals in the Physiological Control of Cell Function,” Physiological Reviews 82, no. 1 (2002): 47–95.

[11] H. Sies and D. P. Jones, “Reactive Oxygen Species (ROS) as Pleiotropic Physiological Signalling Agents,” Nature Reviews Molecular Cell Biology 21, no. 7 (2020): 363–383.

[12] S. Nagaraj, K. Gupta, V. Pisarev, et al., “Altered Recognition of Antigen Is a Mechanism of CD8⁺ T Cell Tolerance in Cancer,” Nature Medicine 13, no. 7 (2007): 828–835.

[13] C. Nathan and A. Cunningham-Bussel, “Beyond Oxidative Stress: An Immunologist's Guide to Reactive Oxygen Species,” Nature Reviews Immunology 13, no. 5 (2013): 349–361.

[14] H. R. Kim, A. Lee, E. J. Choi, et al., “Reactive Oxygen Species Prevent Imiquimod-Induced Psoriatic Dermatitis Through Enhancing Regulatory T Cell Function,” PLoS One 9, no. 3 (2014): e91146.

[15] J. Zhang, C. M. Simpson, J. Berner, et al., “Systematic Identification of Anticancer Drug Targets Reveals a Nucleus-to-Mitochondria ROS-Sensing Pathway,” Cell 186, no. 11 (2023): 2361–2379.

[16] D. N. Douda, M. A. Khan, H. Grasemann, and N. Palaniyar, “SK3 Channel and Mitochondrial ROS Mediate NADPH Oxidase-Independent Netosis Induced by Calcium Influx,” Proceedings of the National Academy of Sciences 112, no. 9 (2015): 2817–2822.

[17] J. Dan Dunn, L. A. Alvarez, X. Zhang, and T. Soldati, “Reactive Oxygen Species and Mitochondria: A Nexus of Cellular Homeostasis,” Redox Biology 6 (2015): 472–485.

[18] L. He, T. He, S. Farrar, L. Ji, T. Liu, and X. Ma, “Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species,” Cellular Physiology and Biochemistry 44, no. 2 (2017): 532–553.

[19] B. Poljsak, D. Šuput, and I. Milisav, “Achieving the Balance Between ROS and Antioxidants: When to Use the Synthetic Antioxidants,” Oxidative Medicine and Cellular Longevity 2013 (2013): 956792.

[20] C. J. Binder, N. Papac-Milicevic, and J. L. Witztum, “Innate Sensing of Oxidation-Specific Epitopes in Health and Disease,” Nature Reviews Immunology 16, no. 8 (2016): 485–497.

[21] M. Bassani-Sternberg, E. Bräunlein, R. Klar, et al., “Direct Identification of Clinically Relevant Neoepitopes Presented on Native Human Melanoma Tissue by Mass Spectrometry,” Nature Communications 7 (2016): 13404.

[22] Y. Zhai, L. Chen, Q. Zhao, et al., “Cysteine Carboxyethylation Generates Neoantigens to Induce HLA-Restricted Autoimmunity,” Science 379, no. 6637 (2023): eabg2482.

[23] U. Seifert, L. P. Bialy, F. Ebstein, et al., “Immunoproteasomes Preserve Protein Homeostasis Upon Interferon-Induced Oxidative Stress,” Cell 142, no. 4 (2010): 613–624.

[24] Z. Deng, B. Li, M. Yang, et al., “Irradiated Microparticles Suppress Prostate Cancer by Tumor Microenvironment Reprogramming and Ferroptosis,” Journal of Nanobiotechnology 22, no. 1 (2024): 225.

[25] H. I. Aksoylar and N. Patsoukis, “Treatment With Exogenously Added Catalase Alters CD8 T Cell Memory Differentiation and Function,” Advanced Biology 7, no. 4 (2023): e2101320.

[26] S. G. Martins, R. Zilhão, S. Thorsteinsdóttir, and A. R. Carlos, “Linking Oxidative Stress and DNA Damage to Changes in the Expression of Extracellular Matrix Components,” Frontiers in Genetics 12 (2021): 673002.

[27] I. E. Shapiro and M. Bassani-Sternberg, “The Impact of Immunopeptidomics: From Basic Research to Clinical Implementation,” Seminars in Immunology 66 (2023): 101727.

[28] C. C. Clement, P. P. Nanaware, T. Yamazaki, et al., “Pleiotropic Consequences of Metabolic Stress for the Major Histocompatibility Complex Class II Molecule Antigen Processing and Presentation Machinery,” Immunity 54, no. 4 (2021): 721–736.e10.

[29] C. M. Ade, M. J. Sporn, S. Das, et al., “Identification of Neoepitope Reactive T-Cell Receptors Guided by HLA-A*03:01 and HLA-A*11:01 Immunopeptidomics,” Journal for Immunotherapy of Cancer 11, no. 9 (2023): e007097.

[30] S. Mitra, S. De Sarkar, A. Pradhan, et al., “Levels of Oxidative Damage and Proinflammatory Cytokines Are Enhanced in Patients With Active Vitiligo,” Free Radical Research 51, no. 11–12 (2017): 986–994.

[31] U. S. Srinivas, B. W. Q. Tan, B. A. Vellayappan, and A. D. Jeyasekharan, “ROS and the DNA Damage Response in Cancer,” Redox Biology 25 (2019): 101084.

[32] S. Maynard, S. H. Schurman, C. Harboe, N. C. de Souza-Pinto, and V. A. Bohr, “Base Excision Repair of Oxidative DNA Damage and Association With Cancer and Aging,” Carcinogenesis 30, no. 1 (2008): 2–10.

[33] M. S. Cooke, M. D. Evans, M. Dizdaroglu, and J. Lunec, “Oxidative DNA Damage: Mechanisms, Mutation, and Disease,” FASEB Journal 17, no. 10 (2003): 1195–1214.

[34] D. Gupta and C. D. Heinen, “The Mismatch Repair-Dependent DNA Damage Response: Mechanisms and Implications,” DNA Repair 78 (2019): 60–69.

[35] D. Guillotin and S. A. Martin, “Exploiting DNA Mismatch Repair Deficiency as a Therapeutic Strategy,” Experimental Cell Research 329, no. 1 (2014): 110–115.

[36] K. W. Caldecott, “Single-Strand Break Repair and Genetic Disease,” Nature Reviews Genetics 9, no. 8 (2008): 619–631.

[37] T. B. M. Permata, Y. Hagiwara, H. Sato, et al., “Base Excision Repair Regulates PD-L1 Expression in Cancer Cells,” Oncogene 38, no. 23 (2019): 4452–4466.

[38] M. J. Schofield and P. Hsieh, “DNA Mismatch Repair: Molecular Mechanisms and Biological Function,” Annual Review of Microbiology 57 (2003): 579–608.

[39] S. Indraccolo, G. Lombardi, M. Fassan, et al., “Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma,” Clinical Cancer Research 25, no. 6 (2019): 1828–1837.

[40] H. Xia, J. McMichael, M. Becker-Hapak, et al., “Computational Prediction of MHC Anchor Locations Guides Neoantigen Identification and Prioritization,” Science Immunology 8, no. 82 (2023): eabg2200.

[41] G. A. Fontana, A. Rigamonti, S. C. Lenzken, et al., “Oxidative Stress Controls the Choice of Alternative Last Exons via a Brahma-BRCA1-CstF Pathway,” Nucleic Acids Research 45, no. 2 (2017): 902–914.

[42] Y. Akaike, K. Masuda, Y. Kuwano, et al., “HuR Regulates Alternative Splicing of the TRA2β Gene in Human Colon Cancer Cells Under Oxidative Stress,” Molecular and Cellular Biology 34, no. 15 (2014): 2857–2873.

[43] C. A. O'Brien and S. L. Wolin, “A Possible Role for the 60-kD Ro Autoantigen in a Discard Pathway for Defective 5S rRNA Precursors,” Genes & Development 8, no. 23 (1994): 2891–2903.

[44] H. Yamagata, J. B. Harley, and M. Reichlin, “Molecular Properties of the Ro/SSA Antigen and Enzyme-Linked Immunosorbent Assay for Quantitation of Antibody,” Journal of Clinical Investigation 74, no. 2 (1984): 625–633.

[45] R. Hal Scofield, B. T. Kurien, S. Ganick, et al., “Modification of Lupus-Associated 60-kDa Ro Protein With the Lipid Oxidation Product 4-hydroxy-2-nonenal Increases Antigenicity and Facilitates Epitope Spreading,” Free Radical Biology and Medicine 38, no. 6 (2005): 719–728.

[46] Y. Wang, H. Xue, M. Aglave, A. Lainé, M. Gallopin, and D. Gautheret, “The Contribution of Uncharted RNA Sequences to Tumor Identity in Lung Adenocarcinoma,” NAR Cancer 4, no. 1 (2022): zcac001.

[47] J. Petersen, A. W. Purcell, and J. Rossjohn, “Post-Translationally Modified T Cell Epitopes: Immune Recognition and Immunotherapy,” Journal of Molecular Medicine 87, no. 11 (2009): 1045–1051.

[48] H. Nguyen, D. Arribas-Layton, I. T. Chow, et al., “Characterizing T Cell Responses to Enzymatically Modified Beta Cell Neo-Epitopes,” Frontiers in Immunology 13 (2022): 1015855.

[49] R. A. Mariuzza, D. Wu, and B. G. Pierce, “Structural Basis for T Cell Recognition of Cancer Neoantigens and Implications for Predicting Neoepitope Immunogenicity,” Frontiers in Immunology 14 (2023): 1303304.

[50] V. Apostolopoulos, E. Yuriev, P. A. Ramsland, et al., “A Glycopeptide in Complex With MHC Class I Uses the GalNAc Residue as an Anchor,” Proceedings of the National Academy of Sciences 100, no. 25 (2003): 15029–15034.

[51] S. A. Malaker, S. A. Penny, L. G. Steadman, et al., “Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia,” Cancer Immunology Research 5, no. 5 (2017): 376–384.

[52] F. Mohammed, M. Cobbold, A. L. Zarling, et al., “Phosphorylation-Dependent Interaction Between Antigenic Peptides and MHC Class I: A Molecular Basis for the Presentation of Transformed Self,” Nature Immunology 9, no. 11 (2008): 1236–1243.

[53] R. V. V. Tatituri, G. F. M. Watts, V. Bhowruth, et al., “Recognition of Microbial and Mammalian Phospholipid Antigens by NKT Cells With Diverse TCRs,” Proceedings of the National Academy of Sciences 110, no. 5 (2013): 1827–1832.

[54] T. Dao, S. S. Mun, Z. Molvi, et al., “A TCR Mimic Monoclonal Antibody Reactive With the ‘Public’ Phospho-Neoantigen pIRS2/HLA-A*02:01 Complex,” JCI Insight 7, no. 5 (2022): e151624.

[55] L. J. Stern, C. Clement, L. Galluzzi, and L. Santambrogio, “Non-Mutational Neoantigens in Disease,” Nature Immunology 25, no. 1 (2024): 29–40.

[56] R. Strollo, C. Vinci, Y. K. S. Man, et al., “Autoantibody and T Cell Responses to Oxidative Post-Translationally Modified Insulin Neoantigenic Peptides in Type 1 Diabetes,” Diabetologia 66, no. 1 (2023): 132–146.

[57] S. Balakrishnan, P. Kumar, and B. S. Prabhakar, “Post-Translational Modifications Contribute to Neoepitopes in Type-1 Diabetes: Challenges for Inducing Antigen-Specific Tolerance,” Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics 1868, no. 10 (2020): 140478.

[58] B. T. Kurien, K. Hensley, M. Bachmann, and R. H. Scofield, “Oxidatively Modified Autoantigens Autoimmune Diseases,” Free Radical Biology and Medicine 41, no. 4 (2006): 549–556.

[59] R. Strollo, C. Vinci, M. H. Arshad, et al., “Antibodies to Post-Translationally Modified Insulin in Type 1 Diabetes,” Diabetologia 58, no. 12 (2015): 2851–2860.

[60] R. Strollo, C. Vinci, N. Napoli, P. Pozzilli, J. Ludvigsson, and A. Nissim, “Antibodies to Post-Translationally Modified Insulin as a Novel Biomarker for Prediction of Type 1 Diabetes in Children,” Diabetologia 60, no. 8 (2017): 1467–1474.

[61] P. Achenbach, K. Koczwara, A. Knopff, H. Naserke, A. G. Ziegler, and E. Bonifacio, “Mature High-Affinity Immune Responses to (Pro)Insulin Anticipate the Autoimmune Cascade That Leads to Type 1 Diabetes,” Journal of Clinical Investigation 114, no. 4 (2004): 589–597.

[62] V. Lampasona and D. Liberati, “Islet Autoantibodies,” Current Diabetes Reports 16, no. 6 (2016): 53.

[63] Z. Rasheed, R. Ahmad, N. Rasheed, and R. Ali, “Enhanced Recognition of Reactive Oxygen Species Damaged Human Serum Albumin by Circulating Systemic Lupus Erythematosus Autoantibodies,” Autoimmunity 40, no. 7 (2007): 512–520.

[64] R. C. Monahan, M. D. van den Beukel, N. V. Borggreven, et al., “Autoantibodies Against Specific Post-Translationally Modified Proteins Are Present in Patients With Lupus and Associate With Major Neuropsychiatric Manifestations,” RMD Open 8, no. 1 (2022): e002079.

[65] J. McHugh, “Gut Metabolite Mediates Neoantigen Generation in as,” Nature Reviews Rheumatology 19, no. 6 (2023): 325.

[66] H. Y. Small, S. Migliarino, M. Czesnikiewicz-Guzik, and T. J. Guzik, “Hypertension: Focus on Autoimmunity and Oxidative Stress,” Free Radical Biology and Medicine 125 (2018): 104–115.

[67] C. F. Lichti and X. Wan, “Using Mass Spectrometry to Identify Neoantigens in Autoimmune Diseases: The Type 1 Diabetes Example,” Seminars in Immunology 66 (2023): 101730.

[68] D. Weiskopf, A. Schwanninger, B. Weinberger, et al., “Oxidative Stress Can Alter the Antigenicity of Immunodominant Peptides,” Journal of Leukocyte Biology 87, no. 1 (2010): 165–172.

[69] J. J. Kelly, N. Bloodworth, Q. Shao, et al., “A Chemical Approach to Assess the Impact of Post-Translational Modification on MHC Peptide Binding and Effector Cell Engagement,” ACS Chemical Biology 19, no. 9 (2024): 1991–2001.

[70] N. Pishesha, T. J. Harmand, and H. L. Ploegh, “A Guide to Antigen Processing and Presentation,” Nature Reviews Immunology 22, no. 12 (2022): 751–764.

[71] C. Thomas and R. Tampé, “MHC I Chaperone Complexes Shaping Immunity,” Current Opinion in Immunology 58 (2019): 9–15.

[72] P. A. Roche and K. Furuta, “The Ins and Outs of MHC Class II-Mediated Antigen Processing and Presentation,” Nature Reviews Immunology 15, no. 4 (2015): 203–216.

[73] M. M. Madeira, Z. Hage, and S. E. Tsirka, “Beyond Myelination: Possible Roles of the Immune Proteasome in Oligodendroglial Homeostasis and Dysfunction,” Frontiers in Neuroscience 16 (2022): 867357.

[74] G. A. Collins and A. L. Goldberg, “The Logic of the 26S Proteasome,” Cell 169, no. 5 (2017): 792–806.

[75] X. Wang, I. E. Chemmama, C. Yu, et al., “The Proteasome-Interacting Ecm29 Protein Disassembles the 26S Proteasome in Response to Oxidative Stress,” Journal of Biological Chemistry 292, no. 39 (2017): 16310–16320.

[76] R. Raynes, L. C. D. Pomatto, and K. J. A. Davies, “Degradation of Oxidized Proteins by the Proteasome: Distinguishing Between the 20S, 26S, and Immunoproteasome Proteolytic Pathways,” Molecular Aspects of Medicine 50 (2016): 41–55.

[77] X. Wang, P. Cimermancic, C. Yu, et al., “Molecular Details Underlying Dynamic Structures and Regulation of the Human 26S Proteasome,” Molecular & Cellular Proteomics 16, no. 5 (2017): 840–854.

[78] M. Basler and M. Groettrup, “On the Role of the Immunoproteasome in Protein Homeostasis,” Cells 10, no. 11 (2021): 3216.

[79] T. Jung and T. Grune, “The Proteasome and the Degradation of Oxidized Proteins: Part I—Structure of Proteasomes,” Redox Biology 1, no. 1 (2013): 178–182.

[80] N. Tanahashi, Y. Murakami, Y. Minami, N. Shimbara, K. B. Hendil, and K. Tanaka, “Hybrid Proteasomes,” Journal of Biological Chemistry 275, no. 19 (2000): 14336–14345.

[81] M. Mishto and J. Liepe, “Post-Translational Peptide Splicing and T Cell Responses,” Trends in Immunology 38, no. 12 (2017): 904–915.

[82] W. T. Soh, H. P. Roetschke, J. A. Cormican, et al., “Protein Degradation by Human 20S Proteasomes Elucidates the Interplay Between Peptide Hydrolysis and Splicing,” Nature Communications 15, no. 1 (2024): 1147.

[83] G. Schmidtke, R. Schregle, G. Alvarez, E. M. Huber, and M. Groettrup, “The 20S Immunoproteasome and Constitutive Proteasome Bind With the Same Affinity to PA28αβ and Equally Degrade Fat10,” Molecular Immunology 113 (2019): 22–30.

[84] T. Shibatani, E. J. Carlson, F. Larabee, A. L. McCormack, K. Früh, and W. R. Skach, “Global Organization and Function of Mammalian Cytosolic Proteasome Pools: Implications for PA28 and 19S Regulatory Complexes,” Molecular Biology of the Cell 17, no. 12 (2006): 4962–4971.

[85] D. H. Wolf and W. Hilt, “The Proteasome: a Proteolytic Nanomachine of Cell Regulation and Waste Disposal,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research 1695, no. 1–3 (2004): 19–31.

[86] S. Heink, D. Ludwig, P. M. Kloetzel, and E. Krüger, “IFN-γ-induced Immune Adaptation of the Proteasome System Is an Accelerated and Transient Response,” Proceedings of the National Academy of Sciences 102, no. 26 (2005): 9241–9246.

[87] M. Lefaki, N. Papaevgeniou, and N. Chondrogianni, “Redox Regulation of Proteasome Function,” Redox Biology 13 (2017): 452–458.

[88] G. Paniagua Soriano, G. De Bruin, H. S. Overkleeft, and B. I. Florea, “Toward Understanding Induction of Oxidative Stress and Apoptosis by Proteasome Inhibitors,” Antioxidants & Redox Signaling 21, no. 17 (2014): 2419–2443.

[89] X. Wang, J. Yen, P. Kaiser, and L. Huang, “Regulation of the 26S Proteasome Complex during Oxidative Stress,” Science Signaling 3, no. 151 (2010): ra88.

[90] M. Demasi, L. E. S. Netto, G. M. Silva, et al., “Redox Regulation of the Proteasome via S-Glutathionylation,” Redox Biology 2 (2014): 44–51.

[91] J. P. Castro, T. Jung, T. Grune, and W. Siems, “4-Hydroxynonenal (HNE) Modified Proteins in Metabolic Diseases,” Free Radical Biology and Medicine 111 (2017): 309–315.

[92] Y. Y. Shih, H. Y. Lin, H. M. Jan, et al., “S-Glutathionylation of Hsp90 Enhances Its Degradation and Correlates With Favorable Prognosis of Breast Cancer,” Redox Biology 57 (2022): 102501.

[93] E. Smakowska, M. Czarna, and H. Janska, “Mitochondrial ATP-Dependent Proteases in Protection Against Accumulation of Carbonylated Proteins,” Mitochondrion 19, no. Pt B (2014): 245–251.

[94] C. T. Aiken, R. M. Kaake, X. Wang, and L. Huang, “Oxidative Stress-Mediated Regulation of Proteasome Complexes,” Molecular & Cellular Proteomics 10, no. 5 (2011): R110.006924.

[95] M. Oberkampf, C. Guillerey, J. Mouriès, et al., “Mitochondrial Reactive Oxygen Species Regulate the Induction of CD8⁺ T Cells by Plasmacytoid Dendritic Cells,” Nature Communications 9, no. 1 (2018): 2241.

[96] D. Granfeldt and C. Dahlgren, “An Intact Cytoskeleton Is Required for Prolonged Respiratory Burst Activity During Neutrophil Phagocytosis,” Inflammation 25, no. 3 (2001): 165–169.

[97] I. Dingjan, L. M. Paardekooper, D. R. J. Verboogen, G. F. von Mollard, M. Ter Beest, and G. van den Bogaart, “VAMP8-mediated NOX2 Recruitment to Endosomes Is Necessary for Antigen Release,” European Journal of Cell Biology 96, no. 7 (2017): 705–714.

[98] I. Dingjan, P. T. A. Linders, L. van den Bekerom, et al., “Oxidized Phagosomal NOX2 Complex Is Replenished From Lysosomes,” Journal of Cell Science 130, no. 7 (2017): 1285–1298.

[99] C. Jancic, A. Savina, C. Wasmeier, et al., “Rab27a Regulates Phagosomal pH and NADPH Oxidase Recruitment to Dendritic Cell Phagosomes,” Nature Cell Biology 9, no. 4 (2007): 367–378.

[100] L. M. Paardekooper, I. Dingjan, P. T. A. Linders, et al., “Human Monocyte-Derived Dendritic Cells Produce Millimolar Concentrations of ROS in Phagosomes Per Second,” Frontiers in Immunology 10 (2019): 1216.

[101] M. V. Baranov, F. Bianchi, A. Schirmacher, et al., “The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation,” iScience 11 (2019): 160–177.

[102] M. Vulcano, S. Dusi, D. Lissandrini, et al., “Toll Receptor-Mediated Regulation of NADPH Oxidase in Human Dendritic Cells,” Journal of Immunology 173, no. 9 (2004): 5749–5756.

[103] C. D. Ellson, K. Davidson, G. J. Ferguson, R. O'Connor, L. R. Stephens, and P. T. Hawkins, “Neutrophils From p40phox-/- Mice Exhibit Severe Defects in NADPH Oxidase Regulation and Oxidant-Dependent Bacterial Killing,” Journal of Experimental Medicine 203, no. 8 (2006): 1927–1937.

[104] A. Savina, C. Jancic, S. Hugues, et al., “NOX2 Controls Phagosomal pH to Regulate Antigen Processing during Crosspresentation by Dendritic Cells,” Cell 126, no. 1 (2006): 205–218.

[105] A. R. Mantegazza, A. Savina, M. Vermeulen, et al., “NADPH Oxidase Controls Phagosomal pH and Antigen Cross-Presentation in Human Dendritic Cells,” Blood 112, no. 12 (2008): 4712–4722.

[106] F. M. Cruz, A. Chan, and K. L. Rock, “Pathways of MHC I Cross-Presentation of Exogenous Antigens,” Seminars in Immunology 66 (2023): 101729.

[107] S. C. Nalle, R. Barreira da Silva, H. Zhang, et al., “Aquaporin-3 Regulates Endosome-To-Cytosol Transfer via Lipid Peroxidation for Cross Presentation,” PLoS One 15, no. 11 (2020): e0238484.

[108] I. Dingjan, D. R. Verboogen, L. M. Paardekooper, et al., “Lipid Peroxidation Causes Endosomal Antigen Release for Cross-Presentation,” Scientific Reports 6 (2016): 22064.

[109] E. R. O. Allan, P. Tailor, D. R. Balce, et al., “NADPH Oxidase Modifies Patterns of MHC Class II-Restricted Epitopic Repertoires Through Redox Control of Antigen Processing,” Journal of Immunology 192, no. 11 (2014): 4989–5001.

[110] F. Gros and S. Muller, “The Role of Lysosomes in Metabolic and Autoimmune Diseases,” Nature Reviews Nephrology 19, no. 6 (2023): 366–383.

[111] L. N. Bavkar, R. S. Patil, S. B. Rooge, M. L. Nalawade, and A. U. Arvindekar, “Acceleration of Protein Glycation by Oxidative Stress and Comparative Role of Antioxidant and Protein Glycation Inhibitor,” Molecular and Cellular Biochemistry 459, no. 1–2 (2019): 61–71.

[112] T. F. O. Lima, M. C. Costa, I. D. Figueiredo, et al., “Curcumin, Alone or in Combination With Aminoguanidine, Increases Antioxidant Defenses and Glycation Product Detoxification in Streptozotocin-Diabetic Rats: A Therapeutic Strategy to Mitigate Glycoxidative Stress,” Oxidative Medicine and Cellular Longevity 2020 (2020): 1036360.

[113] A. Steimle, K. Gronbach, B. Beifuss, et al., “Symbiotic Gut Commensal Bacteria Act as Host Cathepsin S Activity Regulators,” Journal of Autoimmunity 75 (2016): 82–95.

[114] J. Ao, Q. Li, Z. Yang, and Y. Mu, “A Cystatin F Homologue From Large Yellow Croaker (Larimichthys crocea) Inhibits Activity of Multiple Cysteine Proteinases and Ii Chain Processing In Vitro,” Fish & Shellfish Immunology 48 (2016): 62–70.

[115] S. Bono, M. Feligioni, and M. Corbo, “Impaired Antioxidant KEAP1-NRF2 System in Amyotrophic Lateral Sclerosis: NRF2 Activation as a Potential Therapeutic Strategy,” Molecular Neurodegeneration 16, no. 1 (2021): 71.

[116] N. Chen, M. Hu, T. Jiang, P. Xiao, and J. Duan, “Insights Into the Molecular Mechanisms, Structure-Activity Relationships and Application Prospects of Polysaccharides by Regulating Nrf2-mediated Antioxidant Response,” Carbohydrate Polymers 333 (2024): 122003.

[117] W. M. Nauseef, “The Phagocyte NOX2 NADPH Oxidase in Microbial Killing and Cell Signaling,” Current Opinion in Immunology 60 (2019): 130–140.

[118] J. M. Rybicka, D. R. Balce, M. F. Khan, R. M. Krohn, and R. M. Yates, “NADPH Oxidase Activity Controls Phagosomal Proteolysis in Macrophages Through Modulation of the Lumenal Redox Environment of Phagosomes,” Proceedings of the National Academy of Sciences 107, no. 23 (2010): 10496–10501.

[119] M. Trost, L. English, S. Lemieux, M. Courcelles, M. Desjardins, and P. Thibault, “The Phagosomal Proteome in Interferon-γ-Activated Macrophages,” Immunity 30, no. 1 (2009): 143–154.

[120] D. S. Collins, E. R. Unanue, and C. V. Harding, “Reduction of Disulfide Bonds Within Lysosomes Is a Key Step in Antigen Processing,” Journal of Immunology 147, no. 12 (1991): 4054–4059.

[121] M. Yang, C. Haase, J. Viljanen, et al., “Cutting Edge: Processing of Oxidized Peptides in Macrophages Regulates T Cell Activation and Development of Autoimmune Arthritis,” Journal of Immunology 199, no. 12 (2017): 3937–3942.

[122] J. Xu, C. He, Y. Cai, et al., “NCF4 Regulates Antigen Presentation of Cysteine Peptides by Intracellular Oxidative Response and Restricts Activation of Autoreactive and Arthritogenic T Cells,” Redox Biology 72 (2024): 103132.

[123] R. Singh and P. Cresswell, “Defective Cross-Presentation of Viral Antigens in Gilt-Free Mice,” Science 328, no. 5984 (2010): 1394–1398.

[124] A. Giodini and P. Cresswell, “Hsp90-mediated Cytosolic Refolding of Exogenous Proteins Internalized by Dendritic Cells,” EMBO Journal 27, no. 1 (2008): 201–211.

[125] M. A. Haque, P. Li, S. K. Jackson, et al., “Absence of γ-Interferon–inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes,” Journal of Experimental Medicine 195, no. 10 (2002): 1267–1277.

[126] M. K. Semwal, A. K. Hester, Y. Xiao, et al., “Redox Status Regulates Autophagy in Thymic Stromal Cells and Promotes T Cell Tolerance,” Proceedings of the National Academy of Sciences 119, no. 40 (2022): e2204296119.

[127] A. V. Griffith, T. Venables, J. Shi, et al., “Metabolic Damage and Premature Thymus Aging Caused by Stromal Catalase Deficiency,” Cell Reports 12, no. 7 (2015): 1071–1079.

[128] J. Nedjic, M. Aichinger, J. Emmerich, N. Mizushima, and L. Klein, “Autophagy in Thymic Epithelium Shapes the T-Cell Repertoire and Is Essential for Tolerance,” Nature 455, no. 7211 (2008): 396–400.

[129] P. M. Rodrigues, L. G. Sousa, C. Perrod, et al., “LAMP2 Regulates Autophagy in the Thymic Epithelium and Thymic Stroma-Dependent CD4 T Cell Development,” Autophagy 19, no. 2 (2023): 426–439.

[130] J. L. Postoak, W. Song, G. Yang, et al., “Thymic Epithelial Cells Require Lipid Kinase Vps34 for CD4 but Not CD8 T Cell Selection,” Journal of Experimental Medicine 219, no. 10 (2022): e20212554.

[131] V. L. Crotzer and J. S. Blum, “Autophagy and Its Role in MHC-Mediated Antigen Presentation,” Journal of Immunology 182, no. 6 (2009): 3335–3341.

[132] W. Ornatowski, Q. Lu, M. Yegambaram, et al., “Complex Interplay Between Autophagy and Oxidative Stress in the Development of Pulmonary Disease,” Redox Biology 36 (2020): 101679.

[133] Y. Li, L. X. Wang, G. Yang, F. Hao, W. J. Urba, and H. M. Hu, “Efficient Cross-Presentation Depends on Autophagy in Tumor Cells,” Cancer Research 68, no. 17 (2008): 6889–6895.

[134] L. A. Ligeon, M. Pena-Francesch, L. D. Vanoaica, et al., “Oxidation Inhibits Autophagy Protein Deconjugation From Phagosomes to Sustain MHC Class II Restricted Antigen Presentation,” Nature Communications 12, no. 1 (2021): 1508.

[135] J. M. Ireland and E. R. Unanue, “Autophagy in Antigen-Presenting Cells Results in Presentation of Citrullinated Peptides to CD4 T Cells,” Journal of Experimental Medicine 208, no. 13 (2011): 2625–2632.

[136] B. Reynisson, B. Alvarez, S. Paul, B. Peters, and M. Nielsen, “NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved Predictions of MHC Antigen Presentation by Concurrent Motif Deconvolution and Integration of MS MHC Eluted Ligand Data,” Nucleic Acids Research 48, no. W1 (2020): W449–W454.

[137] E. C. Lerner, K. I. Woroniecka, V. M. D'Anniballe, et al., “CD8⁺ T Cells Maintain Killing of MHC-I-Negative Tumor Cells Through the NKG2D-NKG2DL Axis,” Nature Cancer 4, no. 9 (2023): 1258–1272.

[138] H. Zhou, Y. Ma, F. Liu, et al., “Current Advances in Cancer Vaccines Targeting NY-ESO-1 for Solid Cancer Treatment,” Frontiers in Immunology 14 (2023): 1255799.

[139] M. Shinzawa, E. A. Moseman, S. Gossa, et al., “Reversal of the T Cell Immune System Reveals the Molecular Basis for T Cell Lineage Fate Determination in the Thymus,” Nature Immunology 23, no. 5 (2022): 731–742.

[140] B. Y. Wang, Y. Y. Ye, C. Qian, et al., “Stress Increases MHC-I Expression in Dopaminergic Neurons and Induces Autoimmune Activation in Parkinson's Disease,” Neural Regeneration Research 16, no. 12 (2021): 2521–2527.

[141] A. O. Adeshakin, W. Liu, F. O. Adeshakin, et al., “Regulation of ROS in Myeloid-Derived Suppressor Cells Through Targeting Fatty Acid Transport Protein 2 Enhanced anti-Pd-L1 Tumor Immunotherapy,” Cellular Immunology 362 (2021): 104286.

[142] E. J. Swindle, J. M. Brown, M. Rådinger, F. R. DeLeo, and D. D. Metcalfe, “Interferon-γ Enhances Both the Anti-Bacterial and the Pro-Inflammatory Response of Human Mast Cells to Staphylococcus aureus,” Immunology 146, no. 3 (2015): 470–485.

[143] T. S. Mitchell, R. J. Moots, and H. L. Wright, “Janus Kinase Inhibitors Prevent Migration of Rheumatoid Arthritis Neutrophils Towards Interleukin-8, but Do Not Inhibit Priming of the Respiratory Burst or Reactive Oxygen Species Production,” Clinical and Experimental Immunology 189, no. 2 (2017): 250–258.

[144] B. K. Pliyev, T. V. Dimitrieva, and V. G. Savchenko, “Cytokine-Mediated Induction of MHC Class II in Human Neutrophils Is Dependent on NADPH Oxidase Activity,” European Journal of Cell Biology 94, no. 1 (2015): 67–70.

[145] E. Olson and M. Raghavan, “Major Histocompatibility Complex Class I Assembly Within Endolysosomal Pathways,” Current Opinion in Immunology 84 (2023): 102356.

[146] L. M. Achzet, C. J. Davison, M. Shea, I. Sturgeon, and D. A. Jackson, “Oxidative Stress Underlies the Ischemia/Reperfusion-Induced Internalization and Degradation of AMPA Receptors,” International Journal of Molecular Sciences 22, no. 2 (2021): 717.

[147] R. S. Kuna and S. J. Field, “GOLPH3: a Golgi phosphatidylinositol(4)phosphate Effector That Directs Vesicle Trafficking and Drives Cancer,” Journal of Lipid Research 60, no. 2 (2019): 269–275.

[148] M. Ganesan, S. Mathews, E. Makarov, et al., “Acetaldehyde Suppresses HBV-MHC Class I Complex Presentation on Hepatocytes via Induction of ER Stress and Golgi Fragmentation,” American Journal of Physiology—Gastrointestinal and Liver Physiology 319, no. 4 (2020): G432–G442.

[149] G. C. Forcina and S. J. Dixon, “GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis,” Proteomics 19, no. 18 (2019): e1800311.

[150] M. Jia, D. Qin, C. Zhao, et al., “Redox Homeostasis Maintained by GPX4 Facilitates STING Activation,” Nature Immunology 21, no. 7 (2020): 727–735.

[151] F. Veglia, V. A. Tyurin, D. Mohammadyani, et al., “Lipid Bodies Containing Oxidatively Truncated Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer,” Nature Communications 8, no. 1 (2017): 2122.

[152] J. R. Cubillos-Ruiz, P. C. Silberman, M. R. Rutkowski, et al., “ER Stress Sensor XBP1 Controls Anti-Tumor Immunity by Disrupting Dendritic Cell Homeostasis,” Cell 161, no. 7 (2015): 1527–1538.

[153] H. A. Anderson and P. A. Roche, “MHC Class II Association With Lipid Rafts on the Antigen Presenting Cell Surface,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research 1853, no. 4 (2015): 775–780.

[154] N. J. Poloso, A. Muntasell, and P. A. Roche, “MHC Class II Molecules Traffic Into Lipid Rafts During Intracellular Transport,” Journal of Immunology 173, no. 7 (2004): 4539–4546.

[155] H. A. Anderson, E. M. Hiltbold, and P. A. Roche, “Concentration of MHC Class II Molecules in Lipid Rafts Facilitates Antigen Presentation,” Nature Immunology 1, no. 2 (2000): 156–162.

[156] F. Aliche-Djoudi, N. Podechard, M. Chevanne, et al., “Physical and Chemical Modulation of Lipid Rafts by a Dietary n-3 Polyunsaturated Fatty Acid Increases Ethanol-Induced Oxidative Stress,” Free Radical Biology and Medicine 51, no. 11 (2011): 2018–2030.

[157] G. Morris, K. Walder, B. K. Puri, M. Berk, and M. Maes, “The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders,” Molecular Neurobiology 53, no. 7 (2016): 4638–4658.

[158] K. A. Powers, K. Szászi, R. G. Khadaroo, et al., “Oxidative Stress Generated by Hemorrhagic Shock Recruits Toll-Like Receptor 4 to the Plasma Membrane in Macrophages,” Journal of Experimental Medicine 203, no. 8 (2006): 1951–1961.

[159] J. Cuschieri and R. V. Maier, “Oxidative Stress, Lipid Rafts, and Macrophage Reprogramming,” Antioxidants & Redox Signaling 9, no. 9 (2007): 1485–1498.

[160] A. R. Giniatullin, F. Darios, A. Shakirzyanova, B. Davletov, and R. Giniatullin, “SNAP25 Is a Pre-Synaptic Target for the Depressant Action of Reactive Oxygen Species on Transmitter Release,” Journal of Neurochemistry 98, no. 6 (2006): 1789–1797.

[161] L. Chen and D. B. Flies, “Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition,” Nature Reviews Immunology 13, no. 4 (2013): 227–242.

[162] G. Kroemer, C. Galassi, L. Zitvogel, and L. Galluzzi, “Immunogenic Cell Stress and Death,” Nature Immunology 23, no. 4 (2022): 487–500.

[163] X. Lin, K. Kang, P. Chen, et al., “Regulatory Mechanisms of PD-1/PD-L1 in Cancers,” Molecular Cancer 23, no. 1 (2024): 108.

[164] J. A. Williams, X. Tai, and R. J. Hodes, “CD28-CD80/86 and CD40-CD40L Interactions Promote Thymic Tolerance by Regulating Medullary Epithelial Cell and Thymocyte Development,” Critical Reviews in Immunology 35, no. 1 (2015): 59–76.

[165] R. Liu, L. Peng, L. Zhou, Z. Huang, C. Zhou, and C. Huang, “Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications,” Antioxidants 11, no. 5 (2022): 853.

[166] F. Grassi, G. Tell, M. Robbie-Ryan, et al., “Oxidative Stress Causes Bone Loss in Estrogen-Deficient Mice Through Enhanced Bone Marrow Dendritic Cell Activation,” Proceedings of the National Academy of Sciences 104, no. 38 (2007): 15087–15092.

[167] A. Götz, M. C. Ty, and A. Rodriguez, “Oxidative Stress Enhances Dendritic Cell Responses to Plasmodium Falciparum,” Immunohorizons 3, no. 11 (2019): 511–518.

[168] L. Zhang, J. Chen, L. Yan, Q. He, H. Xie, and M. Chen, “Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction,” Frontiers in Pharmacology 12 (2021): 646240.

[169] C. Marchiori, M. Scarpa, A. Kotsafti, et al., “Epithelial CD80 Promotes Immune Surveillance of Colonic Preneoplastic Lesions and Its Expression Is Increased by Oxidative Stress Through STAT3 in Colon Cancer Cells,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 190.

[170] Y. Zhu, L. Gu, X. Lin, et al., “USP19 Exacerbates Lipogenesis and Colorectal Carcinogenesis by Stabilizing ME1,” Cell Reports 37, no. 13 (2021): 110174.

[171] D. Daassi, K. M. Mahoney, and G. J. Freeman, “The Importance of Exosomal PDL1 in Tumour Immune Evasion,” Nature Reviews Immunology 20, no. 4 (2020): 209–215.

[172] C. Glorieux, X. Xia, Y. Q. He, et al., “Regulation of PD-L1 Expression in K-Ras-Driven Cancers Through ROS-Mediated FGFR1 Signaling,” Redox Biology 38 (2021): 101780.

[173] C. Roux, S. M. Jafari, R. Shinde, et al., “Reactive Oxygen Species Modulate Macrophage Immunosuppressive Phenotype Through the Up-Regulation of PD-L1,” Proceedings of the National Academy of Sciences 116, no. 10 (2019): 4326–4335.

[174] N. Wang, L. Song, Y. Xu, et al., “Loss of Scribble Confers Cisplatin Resistance during NSCLC Chemotherapy via Nox2/ROS and Nrf2/PD-L1 Signaling,” EBioMedicine 47 (2019): 65–77.

[175] A. M. Battaglia, A. Sacco, I. Aversa, et al., “Iron-Mediated Oxidative Stress Induces PD-L1 Expression via Activation of c-Myc in Lung Adenocarcinoma,” Frontiers in Cell and Developmental Biology 11 (2023): 1208485.

[176] A. Charras, P. Arvaniti, C. Le Dantec, et al., “JAK Inhibitors and Oxidative Stress Control,” Frontiers in Immunology 10 (2019): 2814.

[177] N. Liu, J. Zhang, M. Yin, et al., “Inhibition of xCT Suppresses the Efficacy of anti-PD-1/L1 Melanoma Treatment Through Exosomal PD-L1-induced Macrophage M2 Polarization,” Molecular Therapy 29, no. 7 (2021): 2321–2334.

[178] H. Liao, X. Chang, L. Gao, et al., “IL-17A Promotes Tumorigenesis and Upregulates PD-L1 Expression in Non-Small Cell Lung Cancer,” Journal of Translational Medicine 21, no. 1 (2023): 828.

[179] P. Shu, H. Liang, J. Zhang, Y. Lin, W. Chen, and D. Zhang, “Reactive Oxygen Species Formation and Its Effect on CD4⁺ T Cell-Mediated Inflammation,” Frontiers in Immunology 14 (2023): 1199233.

[180] J. Cao, S. Liao, F. Zeng, Q. Liao, G. Luo, and Y. Zhou, “Effects of Altered Glycolysis Levels on CD8⁺ T Cell Activation and Function,” Cell Death & Disease 14, no. 7 (2023): 407.

[181] L. A. Sena, S. Li, A. Jairaman, et al., “Mitochondria Are Required for Antigen-Specific T Cell Activation Through Reactive Oxygen Species Signaling,” Immunity 38, no. 2 (2013): 225–236.

[182] X. Yu, Y. Lao, X. L. Teng, et al., “SENP3 Maintains the Stability and Function of Regulatory T Cells via BACH2 Desumoylation,” Nature Communications 9, no. 1 (2018): 3157.

[183] Z. Wu, H. Huang, Q. Han, et al., “SENP7 Senses Oxidative Stress to Sustain Metabolic Fitness and Antitumor Functions of CD8⁺ T Cells,” Journal of Clinical Investigation 132, no. 7 (2022): e155224.

[184] A. Perl, “Oxidative Stress and Endosome Recycling Are Complementary Mechanisms Reorganizing the T-Cell Receptor Signaling Complex in SLE,” Clinical Immunology 142, no. 3 (2012): 219–222.

[185] N. Abdoel, S. Brun, C. Bracho, M. A. Rodríguez, and A. M. Blasini, “Linker for Activation of T Cells Is Displaced From Lipid Rafts and Decreases in Lupus T Cells after Activation via the TCR/CD3 Pathway,” Clinical Immunology 142, no. 3 (2012): 243–251.

[186] S. I. Gringhuis, E. A. M. Papendrecht-van der Voort, A. Leow, E. W. N. Levarht, F. C. Breedveld, and C. L. Verweij, “Effect of Redox Balance Alterations on Cellular Localization of LAT and Downstream T-Cell Receptor Signaling Pathways,” Molecular and Cellular Biology 22, no. 2 (2002): 400–411.

[187] K. A. Gelderman, M. Hultqvist, J. Holmberg, P. Olofsson, and R. Holmdahl, “T Cell Surface Redox Levels Determine T Cell Reactivity and Arthritis Susceptibility,” Proceedings of the National Academy of Sciences 103, no. 34 (2006): 12831–12836.

[188] L. M. McLane, M. S. Abdel-Hakeem, and E. J. Wherry, “CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer,” Annual Review of Immunology 37 (2019): 457–495.

[189] P. Chakraborty, S. Chatterjee, P. Kesarwani, et al., “Thioredoxin-1 Improves the Immunometabolic Phenotype of Antitumor T Cells,” Journal of Biological Chemistry 294, no. 23 (2019): 9198–9212.

[190] P. Kesarwani, A. A. Al-Khami, G. Scurti, et al., “Promoting Thiol Expression Increases the Durability of Antitumor T-Cell Functions,” Cancer Research 74, no. 21 (2014): 6036–6047.

[191] C. Shi, Q. Zhang, Y. Yao, et al., “Targeting the Activity of T Cells by Membrane Surface Redox Regulation for Cancer Theranostics,” Nature Nanotechnology 18, no. 1 (2023): 86–97.

[192] L. Simula, M. Fumagalli, L. Vimeux, et al., “Mitochondrial Metabolism Sustains CD8⁺ T Cell Migration for an Efficient Infiltration Into Solid Tumors,” Nature Communications 15, no. 1 (2024): 2203.

[193] N. E. Scharping, D. B. Rivadeneira, A. V. Menk, et al., “Mitochondrial Stress Induced by Continuous Stimulation under Hypoxia Rapidly Drives T Cell Exhaustion,” Nature Immunology 22, no. 2 (2021): 205–215.

[194] A. T. Ruffin, A. R. Cillo, T. Tabib, et al., “B Cell Signatures and Tertiary Lymphoid Structures Contribute to Outcome in Head and Neck Squamous Cell Carcinoma,” Nature Communications 12, no. 1 (2021): 3349.

[195] A. B. Weiner, T. Vidotto, Y. Liu, et al., “Plasma Cells Are Enriched in Localized Prostate Cancer in Black Men and Are Associated With Improved Outcomes,” Nature Communications 12, no. 1 (2021): 935.

[196] W. H. Fridman, M. Meylan, F. Petitprez, C. M. Sun, A. Italiano, and C. Sautès-Fridman, “B Cells and Tertiary Lymphoid Structures as Determinants of Tumour Immune Contexture and Clinical Outcome,” Nature Reviews Clinical Oncology 19, no. 7 (2022): 441–457.

[197] M. L. Wheeler and A. L. Defranco, “Prolonged Production of Reactive Oxygen Species in Response to B Cell Receptor Stimulation Promotes B Cell Activation and Proliferation,” Journal of Immunology 189, no. 9 (2012): 4405–4416.

[198] Y. Y. Feng, M. Tang, M. Suzuki, et al., “Essential Role of NADPH Oxidase-Dependent Production of Reactive Oxygen Species in Maintenance of Sustained B Cell Receptor Signaling and B Cell Proliferation,” Journal of Immunology 202, no. 9 (2019): 2546–2557.

[199] S. L. Nutt, P. Urbánek, A. Rolink, and M. Busslinger, “Essential Functions of Pax5 (BSAP) in Pro-B Cell Development: Difference between Fetal and Adult B Lymphopoiesis and Reduced V-To-DJ Recombination at the IgH Locus,” Genes & Development 11, no. 4 (1997): 476–491.

[200] H. Zhang, L. Wang, and Y. Chu, “Reactive Oxygen Species: The Signal Regulator of B Cell,” Free Radical Biology and Medicine 142 (2019): 16–22.

[201] H. Y. Yang, J. Kim, K. Y. Lee, and Y. S. Jang, “Rac/ROS-Related Protein Kinase C and phosphatidylinositol-3-kinase Signaling Are Involved in a Negative Regulating Cascade in B Cell Activation by Antibody-Mediated Cross-Linking of MHC Class II Molecules,” Molecular Immunology 47, no. 4 (2010): 706–712.

[202] H. T. Zeng, Y. Liu, M. Zhao, et al., “Modulating Oxidative Stress in B Cells Promotes Immunotherapy in Food Allergy,” Oxidative Medicine and Cellular Longevity 2022 (2022): 3605977.

[203] Y. Tohyama, T. Takano, and H. Yamamura, “B Cell Responses to Oxidative Stress,” Current Pharmaceutical Design 10, no. 8 (2004): 835–839.

[204] M. Bertolotti, R. Sitia, and A. Rubartelli, “On the Redox Control of B Lymphocyte Differentiation and Function,” Antioxidants & Redox Signaling 16, no. 10 (2012): 1139–1149.

[205] H. F. Bradford, T. C. R. McDonnell, A. Stewart, et al., “Thioredoxin Is a Metabolic Rheostat Controlling Regulatory B Cells,” Nature Immunology 25, no. 5 (2024): 873–885.

[206] B. Zidi, C. Vincent-Fabert, L. Pouyet, et al., “TP53INP1 Deficiency Maintains Murine B Lymphopoiesis in Aged Bone Marrow Through Redox-Controlled IL-7R/STAT5 Signaling,” Proceedings of the National Academy of Sciences 116, no. 1 (2019): 211–216.

[207] M. Ogura, T. Inoue, J. Yamaki, M. K. Homma, T. Kurosaki, and Y. Homma, “Mitochondrial Reactive Oxygen Species Suppress Humoral Immune Response Through Reduction of CD19 Expression in B Cells in Mice,” European Journal of Immunology 47, no. 2 (2017): 406–418.

[208] S. Bruzzì, S. Sutti, G. Giudici, et al., “B2-Lymphocyte Responses to Oxidative Stress-Derived Antigens Contribute to the Evolution of Nonalcoholic Fatty Liver Disease (NAFLD),” Free Radical Biology and Medicine 124 (2018): 249–259.

[209] E. Albano, “Immune Response Towards Lipid Peroxidation Products as a Predictor of Progression of Non-Alcoholic Fatty Liver Disease to Advanced Fibrosis,” Gut 54, no. 7 (2005): 987–993.

[210] S. A. Rajput, A. Shaukat, I. R. Rajput, et al., “Ginsenoside Rb1 Prevents Deoxynivalenol-Induced Immune Injury via Alleviating Oxidative Stress and Apoptosis in Mice,” Ecotoxicology and Environmental Safety 220 (2021): 112333.

[211] A. Shaukat, Y. Guo, K. Jiang, et al., “Ginsenoside Rb1 Ameliorates Staphylococcus aureus-Induced Acute Lung Injury Through Attenuating NF-κB and MAPK Activation,” Microbial Pathogenesis 132 (2019): 302–312.

[212] J. Ma, K. Wei, H. Zhang, et al., “Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8⁺ T Cells,” Cancer Immunology Research 6, no. 9 (2018): 1057–1068.

[213] Z. Hu, X. L. Teng, T. Zhang, et al., “SENP3 Senses Oxidative Stress to Facilitate STING-Dependent Dendritic Cell Antitumor Function,” Molecular Cell 81, no. 5 (2021): 940–952.e5.

[214] Y. Jo, J. A. Shim, J. W. Jeong, et al., “Targeting ROS-Sensing Nrf2 Potentiates Anti-Tumor Immunity of Intratumoral CD8⁺ T and CAR-T Cells,” Molecular Therapy 32, no. 11 (2024): 3879–3894.

[215] L. Baird and M. Yamamoto, “Immunoediting of KEAP1-NRF2 Mutant Tumours Is Required to Circumvent NRF2-mediated Immune Surveillance,” Redox Biology 67 (2023): 102904.

[216] N. A. Osna, R. L. White, S. Todero, et al., “Ethanol-Induced Oxidative Stress Suppresses Generation of Peptides for Antigen Presentation by Hepatoma Cells,” Hepatology 45, no. 1 (2007): 53–61.

[217] A. H. Capietto and L. Delamarre, “Peroxynitrite Promotes Immune Evasion by Reducing Tumor Antigenicity,” Cell Reports Medicine 3, no. 10 (2022): 100787.

[218] E. N. Tcyganov, E. Sanseviero, D. Marvel, et al., “Peroxynitrite in the Tumor Microenvironment Changes the Profile of Antigens Allowing Escape From Cancer Immunotherapy,” Cancer Cell 40, no. 10 (2022): 1173–1189.e6.

[219] X. Si, M. Shao, X. Teng, et al., “Mitochondrial Isocitrate Dehydrogenase Impedes Car T Cell Function by Restraining Antioxidant Metabolism and Histone Acetylation,” Cell Metabolism 36, no. 1 (2024): 176–192.e10.

[220] X. Zhu, R. Liang, T. Lan, et al., “Tumor-Associated Macrophage-Specific CD155 Contributes to M2-phenotype Transition, Immunosuppression, and Tumor Progression in Colorectal Cancer,” Journal for Immunotherapy of Cancer 10, no. 9 (2022): e004219.

[221] K. Inagaki, S. Kunisho, H. Takigawa, et al., “Role of Tumor-Associated Macrophages at the Invasive Front in Human Colorectal Cancer Progression,” Cancer science 112, no. 7 (2021): 2692–2704.

[222] A. Płóciennikowska, A. Hromada-Judycka, K. Borzęcka, and K. Kwiatkowska, “Co-Operation of TLR4 and Raft Proteins in LPS-Induced Pro-Inflammatory Signaling,” Cellular and Molecular Life Sciences 72, no. 3 (2015): 557–581.

[223] J. Zhou, Z. Peng, and J. Wang, “Trelagliptin Alleviates Lipopolysaccharide (LPS)-Induced Inflammation and Oxidative Stress in Acute Lung Injury Mice,” Inflammation 44, no. 4 (2021): 1507–1517.

[224] F. K. Mediesse, T. Boudjeko, A. Hasitha, M. Gangadhar, W. F. Mbacham, and P. Yogeeswari, “Inhibition of Lipopolysaccharide (LPS)-Induced Neuroinflammatory Response by Polysaccharide Fractions of Khaya Grandifoliola (C.D.C.) Stem Bark, Cryptolepis Sanguinolenta (Lindl.) Schltr and Cymbopogon citratus Stapf Leaves in Raw 264.7 Macrophages and U87 Glioblastoma Cells,” BMC Complementary and Alternative Medicine 18, no. 1 (2018): 86.

[225] M. J. Morgan and Z. Liu, “Crosstalk of Reactive Oxygen Species and NF-κB Signaling,” Cell Research 21, no. 1 (2011): 103–115.

[226] S. K. Arora, N. Naqvi, A. Alam, et al., “Mycobacterium Smegmatis Bacteria Expressing Mycobacterium Tuberculosis-Specific Rv1954A Induce Macrophage Activation and Modulate the Immune Response,” Frontiers in Cellular and Infection Microbiology 10 (2020): 564565.

[227] I. S. Grewal and R. A. Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation,” Immunological Reviews 153 (1996): 85–106.

[228] L. Wang, Z. Cao, Z. Wang, J. Guo, and J. Wen, “Reactive Oxygen Species Associated Immunoregulation Post Influenza Virus Infection,” Frontiers in Immunology 13 (2022): 927593.

[229] R. Cecchini and A. L. Cecchini, “SARS-CoV-2 Infection Pathogenesis Is Related to Oxidative Stress as a Response to Aggression,” Medical Hypotheses 143 (2020): 110102.

[230] J. Wieczfinska, P. Kleniewska, and R. Pawliczak, “Oxidative Stress-Related Mechanisms in SARS-CoV-2 Infections,” Oxidative Medicine and Cellular Longevity 2022 (2022): 5589089.

[231] N. G. Laniewski and J. M. Grayson, “Antioxidant Treatment Reduces Expansion and Contraction of Antigen-Specific CD8⁺ T Cells during Primary but Not Secondary Viral Infection,” Journal of Virology 78, no. 20 (2004): 11246–11257.

[232] K. Yuan, Y. Lei, H. N. Chen, et al., “HBV-Induced ROS Accumulation Promotes Hepatocarcinogenesis Through Snail-Mediated Epigenetic Silencing of SOCS3,” Cell Death & Differentiation 23, no. 4 (2016): 616–627.

[233] R. Wang, C. Yin, X. X. Li, et al., “Reduced SOD2 Expression Is Associated With Mortality of Hepatocellular Carcinoma Patients in a Mutant p53-dependent Manner,” Aging 8, no. 6 (2016): 1184–1200.

[234] Y. Liu, J. Z. Guo, Y. Liu, et al., “Nuclear Lactate Dehydrogenase A Senses ROS to Produce α-hydroxybutyrate for HPV-Induced Cervical Tumor Growth,” Nature Communications 9, no. 1 (2018): 4429.

[235] N. A. Osna, F. Bardag-Gorce, R. L. White, S. A. Weinman, T. M. Donohue, , and K. K. Kharbanda, “Ethanol and Hepatitis C Virus Suppress Peptide-MHC Class I Presentation in Hepatocytes by Altering Proteasome Function,” Alcoholism: Clinical and Experimental Research 36, no. 12 (2012): 2028–2035.

[236] J. D. Stuart, E. Salinas, and A. Grakoui, “Immune System Control of Hepatitis C Virus Infection,” Current Opinion in Virology 46 (2021): 36–44.

[237] Y. Chen Wongworawat, M. Filippova, V. M. Williams, V. Filippov, and P. J. Duerksen-Hughes, “Chronic Oxidative Stress Increases the Integration Frequency of Foreign DNA and Human Papillomavirus 16 in Human Keratinocytes,” American Journal of Cancer Research 6, no. 4 (2016): 764–780.

[238] F. De Marco, “Oxidative Stress and HPV Carcinogenesis,” Viruses 5, no. 2 (2013): 708–731.

[239] S. Renken, T. Nakajima, I. Magalhaes, et al., “Targeting of Nrf2 Improves Antitumoral Responses by Human NK Cells, TIL and CAR T Cells During Oxidative Stress,” Journal for Immunotherapy of Cancer 10, no. 6 (2022): e004458.

[240] S. Tan, Z. Zheng, T. Liu, X. Yao, M. Yu, and Y. Ji, “Schisandrin B Induced ROS-Mediated Autophagy and Th1/Th2 Imbalance via Selenoproteins in Hepa1-6 Cells,” Frontiers in Immunology 13 (2022): 857069.

[241] J. Berbecki, K. Mitosek-Szewczyk, J. Kurzepa, M. Nastaj, K. Łobejko, and Z. Stelmasiak, “Processes of Free Radical Lipid Peroxidation With a Particular Regard to the Role of Paraoxonase-1 in the Pathogenesis of Multiple Sclerosis,” Wiadomosci lekarskie 64, no. 1 (2011): 31–36.

[242] M. J. Smallwood, A. Nissim, A. R. Knight, M. Whiteman, R. Haigh, and P. G. Winyard, “Oxidative Stress in Autoimmune Rheumatic Diseases,” Free Radical Biology and Medicine 125 (2018): 3–14.

[243] J. Zhang, Y. Wang, M. Fan, et al., “Reactive Oxygen Species Regulation by NCF1 Governs Ferroptosis Susceptibility of Kupffer Cells to MASH,” Cell Metabolism 36, no. 8 (2024): 1745–1763.e6.

[244] J. Muri and M. Kopf, “Redox Regulation of Immunometabolism,” Nature Reviews Immunology 21, no. 6 (2021): 363–381.

[245] E. A. Veal, Z. E. Underwood, L. E. Tomalin, B. A. Morgan, and C. S. Pillay, “Hyperoxidation of Peroxiredoxins: Gain or Loss of Function?,” Antioxidants & Redox Signaling 28, no. 7 (2018): 574–590.

[246] V. Branco, J. Pimentel, M. A. Brito, and C. Carvalho, “Thioredoxin, Glutathione and Related Molecules in Tumors of the Nervous System,” Current Medicinal Chemistry 27, no. 12 (2020): 1878–1900.

[247] S. Chandran and D. Binninger, “Role of Oxidative Stress, Methionine Oxidation and Methionine Sulfoxide Reductases (MSR) in Alzheimer's Disease,” Antioxidants 13, no. 1 (2023): 21.

[248] D. Ezeriņa, Y. Takano, K. Hanaoka, Y. Urano, and T. P. Dick, “N-Acetyl Cysteine Functions as a Fast-Acting Antioxidant by Triggering Intracellular H₂S and Sulfane Sulfur Production,” Cell Chemical Biology 25, no. 4 (2018): 447–459.e4.

[249] L. Zhi, I. V. Ustyugova, X. Chen, Q. Zhang, and M. X. Wu, “Enhanced Th17 Differentiation and Aggravated Arthritis in IEX-1-deficient Mice by Mitochondrial Reactive Oxygen Species-Mediated Signaling,” Journal of Immunology 189, no. 4 (2012): 1639–1647.

[250] K. M. Nash, I. T. Schiefer, and Z. A. Shah, “Development of a Reactive Oxygen Species-Sensitive Nitric Oxide Synthase Inhibitor for the Treatment of Ischemic Stroke,” Free Radical Biology and Medicine 115 (2018): 395–404.

[251] K. Morimoto, T. Hasegawa, A. Tanaka, et al., “Free-Radical Scavenger Edaravone Inhibits Both Formation and Development of Abdominal Aortic Aneurysm in Rats,” Journal of Vascular Surgery 55, no. 6 (2012): 1749–1758.

[252] G. Teixeira, C. Szyndralewiez, S. Molango, et al., “Therapeutic Potential of NADPH Oxidase 1/4 Inhibitors,” British Journal of Pharmacology 174, no. 12 (2017): 1647–1669.

[253] L. Liu, W. Zhang, T. Liu, et al., “The Physiological Metabolite α-ketoglutarate Ameliorates Osteoarthritis by Regulating Mitophagy and Oxidative Stress,” Redox Biology 62 (2023): 102663.

[254] Y. Kuang, X. Han, M. Xu, Y. Wang, Y. Zhao, and Q. Yang, “Oxaloacetate Ameliorates Chemical Liver Injury via Oxidative Stress Reduction and Enhancement of Bioenergetic Fluxes,” International Journal of Molecular Sciences 19, no. 6 (2018): 1626.

[255] Y. Shinohara and M. Tsukimoto, “Adenine Nucleotides Attenuate Murine T Cell Activation Induced by Concanavalin A or T Cell Receptor Stimulation,” Frontiers in Pharmacology 8 (2018): 986.

[256] C. L. Kuo, C. W. Chi, and T. Y. Liu, “The Anti-Inflammatory Potential of Berberine In Vitro and In Vivo,” Cancer Letters 203, no. 2 (2004): 127–137.

[257] I. Jutooru, A. S. Guthrie, G. Chadalapaka, et al., “Mechanism of Action of Phenethylisothiocyanate and Other Reactive Oxygen Species-Inducing Anticancer Agents,” Molecular and Cellular Biology 34, no. 13 (2014): 2382–2395.

[258] T. Nakanishi, K. Mukai, H. Yumoto, K. Hirao, Y. Hosokawa, and T. Matsuo, “Anti-Inflammatory Effect of Catechin on Cultured Human Dental Pulp Cells Affected by Bacteria-Derived Factors,” European Journal of Oral Sciences 118, no. 2 (2010): 145–150.

[259] L. Li, R. Mao, S. Yuan, et al., “NCF4 Attenuates Colorectal Cancer Progression by Modulating Inflammasome Activation and Immune Surveillance,” Nature Communications 15, no. 1 (2024): 5170.

[260] C. He, H. Luo, A. Coelho, et al., “NCF4 Dependent Intracellular Reactive Oxygen Species Regulate Plasma Cell Formation,” Redox Biology 56 (2022): 102422.

[261] H. A. Doyle and M. J. Mamula, “Posttranslational Modifications of Self-Antigens,” Annals of the New York Academy of Sciences 1050 (2005): 1–9.

[262] L. K. Bockenstedt, R. J. Gee, and M. J. Mamula, “Self-Peptides in the Initiation of Lupus Autoimmunity,” Journal of Immunology 154, no. 7 (1995): 3516–3524.

[263] H. R. Griffiths, “Is the Generation of Neo-Antigenic Determinants by Free Radicals Central to the Development of Autoimmune Rheumatoid Disease?,” Autoimmunity Reviews 7, no. 7 (2008): 544–549.

[264] B. T. Kurien and R. H. Scofield, “Autoimmunity and Oxidatively Modified Autoantigens,” Autoimmunity Reviews 7, no. 7 (2008): 567–573.

[265] S. Blount, H. Griffiths, P. Emery, and J. Lunec, “Reactive Oxygen Species Modify Human DNA, Eliciting a More Discriminating Antigen for the Diagnosis of Systemic Lupus Erythematosus,” Clinical and Experimental Immunology 81, no. 3 (1990): 384–389.

[266] E. A. James, R. Mallone, S. C. Kent, and T. P. DiLorenzo, “T-Cell Epitopes and Neo-Epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal,” Diabetes 69, no. 7 (2020): 1311–1335.

[267] X. Chen, N. Xie, L. Feng, et al, “Oxidative Stress in Diabetes Mellitus and Its Complications: From Pathophysiology to Therapeutic Strategies,” Chinese Medical Journal 138, no. 1 (2025): 15–27.

[268] J. W. McGinty, I. T. Chow, C. Greenbaum, J. Odegard, W. W. Kwok, and E. A. James, “Recognition of Posttranslationally Modified GAD65 Epitopes in Subjects With Type 1 Diabetes,” Diabetes 63, no. 9 (2014): 3033–3040.

[269] M. L. Marré and J. D. Piganelli, “Environmental Factors Contribute to β Cell Endoplasmic Reticulum Stress and Neo-Antigen Formation in Type 1 Diabetes,” Frontiers in Endocrinology 8 (2017): 262.

[270] E. A. James, M. Pietropaolo, and M. J. Mamula, “Immune Recognition of β-Cells: Neoepitopes as Key Players in the Loss of Tolerance,” Diabetes 67, no. 6 (2018): 1035–1042.

[271] S. Mukhopadhyay, M. G. Vander Heiden, and F. McCormick, “The Metabolic Landscape of RAS-Driven Cancers From Biology to Therapy,” Nature Cancer 2, no. 3 (2021): 271–283.

[272] R. Cheng, F. Li, M. Zhang, et al., “A Novel Protein Rason Encoded by a lncRNA Controls Oncogenic RAS Signaling in KRAS Mutant Cancers,” Cell Research 33, no. 1 (2023): 30–45.

[273] M. R. Janes, J. Zhang, L. S. Li, et al., “Targeting KRAS Mutant Cancers With a Covalent G12C-Specific Inhibitor,” Cell 172, no. 3 (2018): 578–589.e17.

[274] H. S. Solanki, E. A. Welsh, B. Fang, et al., “Cell Type-Specific Adaptive Signaling Responses to KRAS(G12C) Inhibition,” Clinical Cancer Research 27, no. 9 (2021): 2533–2548.

[275] Z. Zhang, P. J. Rohweder, C. Ongpipattanakul, et al., “A Covalent Inhibitor of K-Ras(G12C) Induces MHC Class I Presentation of Haptenated Peptide Neoepitopes Targetable by Immunotherapy,” Cancer Cell 40, no. 9 (2022): 1060–1069.e7.

[276] J. Canon, K. Rex, A. Y. Saiki, et al., “The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity,” Nature 575, no. 7781 (2019): 217–223.

[277] D. Romero, “Two New Agents Target KRAS G12c,” Nature Reviews Clinical Oncology 17, no. 1 (2020): 6.

[278] R. Yaeger, J. Weiss, M. S. Pelster, et al., “Adagrasib With or Without Cetuximab in Colorectal Cancer With Mutated KRAS G12C,” New England Journal of Medicine 388, no. 1 (2023): 44–54.

[279] T. S. Bekaii-Saab, R. Yaeger, A. I. Spira, et al., “Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation,” Journal of Clinical Oncology 41, no. 25 (2023): 4097–4106.

[280] J. Wang, P. Martin-Romano, P. Cassier, et al., “Phase I Study of JNJ-74699157 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation,” Oncologist 27, no. 7 (2022): 536–553.

[281] M. Nagasaka, Y. Li, A. Sukari, S. H. I. Ou, M. N. Al-Hallak, and A. S. Azmi, “KRAS G12C Game of Thrones, Which Direct KRAS Inhibitor Will Claim the Iron Throne?,” Cancer Treatment Reviews 84 (2020): 101974.

[282] P. Malekzadeh, R. Yossef, G. Cafri, et al., “Antigen Experienced T Cells From Peripheral Blood Recognize p53 Neoantigens,” Clinical Cancer Research 26, no. 6 (2020): 1267–1276.

[283] M. Kabir, N. Sun, X. Hu, et al., “Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53,” Journal of the American Chemical Society 145, no. 27 (2023): 14932–14944.

[284] J. Singh, R. C. Petter, T. A. Baillie, and A. Whitty, “The Resurgence of Covalent Drugs,” Nature Reviews Drug Discovery 10, no. 4 (2011): 307–317.

[285] A. S. Kalgutkar and D. K. Dalvie, “Drug Discovery for a New Generation of Covalent Drugs,” Expert Opinion on Drug Discovery 7, no. 7 (2012): 561–581.

[286] Q. Li, Q. Chen, P. C. Klauser, et al., “Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics,” Cell 182, no. 1 (2020): 85–97.e16.

[287] R. Fernandez-Santamaria, A. Ariza, T. D. Fernandez, et al., “Advances and Highlights in T and B Cell Responses to Drug Antigens,” Allergy 77, no. 4 (2022): 1129–1138.

[288] P. T. Illing, J. P. Vivian, N. L. Dudek, et al., “Immune Self-Reactivity Triggered by Drug-Modified HLA-Peptide Repertoire,” Nature 486, no. 7404 (2012): 554–558.

[289] Y. Wu, L. Chen, J. Chen, et al., “Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin,” Drug Metabolism and Disposition 51, no. 1 (2023): 8–16.

[290] Z. Zou, H. Chang, H. Li, and S. Wang, “Induction of Reactive Oxygen Species: An Emerging Approach for Cancer Therapy,” Apoptosis 22, no. 11 (2017): 1321–1335.

[291] A. Henningham, S. Döhrmann, V. Nizet, and J. N. Cole, “Mechanisms of Group A Streptococcus Resistance to Reactive Oxygen Species,” FEMS Microbiology Reviews 39, no. 4 (2015): 488–508.

[292] M. P. Murphy, “How Mitochondria Produce Reactive Oxygen Species,” Biochemical Journal 417, no. 1 (2009): 1–13.

[293] L. A. Sena and N. S. Chandel, “Physiological Roles of Mitochondrial Reactive Oxygen Species,” Molecular Cell 48, no. 2 (2012): 158–167.

[294] S. Choudhary, I. Boldogh, and A. R. Brasier, “Inside-Out Signaling Pathways From Nuclear Reactive Oxygen Species Control Pulmonary Innate Immunity,” Journal of Innate Immunity 8, no. 2 (2016): 143–155.

[295] K. Jomova, S. Y. Alomar, S. H. Alwasel, E. Nepovimova, K. Kuca, and M. Valko, “Several Lines of Antioxidant Defense Against Oxidative Stress: Antioxidant Enzymes, Nanomaterials With Multiple Enzyme-Mimicking Activities, and Low-Molecular-Weight Antioxidants,” Archives of Toxicology 98, no. 5 (2024): 1323–1367.

[296] S. Y. Phua, B. De Smet, C. Remacle, K. X. Chan, and F. Van Breusegem, “Reactive Oxygen Species and Organellar Signaling,” Journal of Experimental Botany 72, no. 16 (2021): 5807–5824.

[297] C. Mas-Bargues, E. García-Domínguez, and C. Borrás, “Recent Approaches to Determine Static and Dynamic Redox State-Related Parameters,” Antioxidants 11, no. 5 (2022): 864.

[298] E. L. Yarosz and C. H. Chang, “The Role of Reactive Oxygen Species in Regulating T Cell-Mediated Immunity and Disease,” Immune Network 18, no. 1 (2018): e14.

[299] Y. C. Hung, T. L. Pan, and W. L. Hu, “Roles of Reactive Oxygen Species in Anticancer Therapy With Salvia Miltiorrhiza Bunge,” Oxidative Medicine and Cellular Longevity 2016 (2016): 5293284.

[300] S. Zeng, L. Yang, Q. Yan, L. Gao, H. Lu, and P. Yan, “Nox1/4 Dual Inhibitor GKT137831 Attenuates Hypertensive Cardiac Remodelling Associating With the Inhibition of ADAM17-dependent Proinflammatory Cytokines-Induced Signalling Pathways in the Rats With Abdominal Artery Constriction,” Biomedicine & Pharmacotherapy 109 (2019): 1907–1914.

[301] M. Sedeek, A. Gutsol, A. C. Montezano, et al., “Renoprotective Effects of a Novel Nox1/4 Inhibitor in a Mouse Model of Type 2 Diabetes,” Clinical Science 124, no. 3 (2013): 191–202.

[302] K. Ford, C. J. Hanley, M. Mellone, et al., “NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion From Tumors,” Cancer Research 80, no. 9 (2020): 1846–1860.

[303] T. Yamamoto, H. Nakano, K. Shiomi, et al., “Identification and Characterization of a Novel NADPH Oxidase 1 (Nox1) Inhibitor That Suppresses Proliferation of Colon and Stomach Cancer Cells,” Biological and Pharmaceutical Bulletin 41, no. 3 (2018): 419–426.

[304] B. Laleu, F. Gaggini, M. Orchard, et al., “First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis,” Journal of Medicinal Chemistry 53, no. 21 (2010): 7715–7730.

[305] V. T. V. Dao, M. H. Elbatreek, S. Altenhöfer, et al., “Isoform-Selective NADPH Oxidase Inhibitor Panel for Pharmacological Target Validation,” Free Radical Biology and Medicine 148 (2020): 60–69.

[306] J. J. Cha, H. S. Min, K. T. Kim, et al., “APX-115, a First-in-Class Pan-NADPH Oxidase (Nox) Inhibitor, Protects db/db Mice From Renal Injury,” Laboratory Investigation 97, no. 4 (2017): 419–431.

[307] Y. Zhang, P. Murugesan, K. Huang, and H. Cai, “NADPH Oxidases and Oxidase Crosstalk in Cardiovascular Diseases: Novel Therapeutic Targets,” Nature Reviews Cardiology 17, no. 3 (2020): 170–194.

[308] B. Griess, S. Mir, K. Datta, and M. Teoh-Fitzgerald, “Scavenging Reactive Oxygen Species Selectively Inhibits M2 Macrophage Polarization and Their Pro-Tumorigenic Function in Part, via Stat3 Suppression,” Free Radical Biology and Medicine 147 (2020): 48–60.

[309] G. F. Kelso, C. M. Porteous, C. V. Coulter, et al., “Selective Targeting of a Redox-Active Ubiquinone to Mitochondria Within Cells,” Journal of Biological Chemistry 276, no. 7 (2001): 4588–4596.

[310] R. A. Sosa, C. Murphey, R. R. Robinson, and T. G. Forsthuber, “IFN-γ Ameliorates Autoimmune Encephalomyelitis by Limiting Myelin Lipid Peroxidation,” Proceedings of the National Academy of Sciences 112, no. 36 (2015): E5038–E5047.

[311] J. Zuo, Z. Zhang, M. Li, et al., “The Crosstalk Between Reactive Oxygen Species and Noncoding RNAs: From Cancer Code to Drug Role,” Molecular Cancer 21, no. 1 (2022): 30.

[312] M. Dewaele, H. Maes, and P. Agostinis, “ROS-Mediated Mechanisms of Autophagy Stimulation and Their Relevance in Cancer Therapy,” Autophagy 6, no. 7 (2010): 838–854.

[313] J. R. Kirshner, S. He, V. Balasubramanyam, et al., “Elesclomol Induces Cancer Cell Apoptosis Through Oxidative Stress,” Molecular Cancer Therapeutics 7, no. 8 (2008): 2319–2327.

[314] S. O'Day, R. Gonzalez, D. Lawson, et al., “Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma,” Journal of Clinical Oncology 27, no. 32 (2009): 5452–5458.

[315] B. Guo, F. Yang, L. Zhang, et al., “Cuproptosis Induced by ROS Responsive Nanoparticles With Elesclomol and Copper Combined With αPD-L1 for Enhanced Cancer Immunotherapy,” Advanced Materials 35, no. 22 (2023): e2212267.

[316] L. Zhao, B. Zhong, Y. Zhu, et al., “Nitrovin (Difurazone), an Antibacterial Growth Promoter, Induces ROS-Mediated Paraptosis-Like Cell Death by Targeting Thioredoxin Reductase 1 (TrxR1),” Biochemical Pharmacology 210 (2023): 115487.

[317] N. Akhter, A. Wilson, H. Arefanian, et al., “Endoplasmic Reticulum Stress Promotes the Expression of TNF-α in THP-1 Cells by Mechanisms Involving ROS/CHOP/HIF-1α and MAPK/NF-κB Pathways,” International Journal of Molecular Sciences 24, no. 20 (2023): 15186.

[318] M. Songbo, H. Lang, C. Xinyong, X. Bin, Z. Ping, and S. Liang, “Oxidative Stress Injury in Doxorubicin-Induced Cardiotoxicity,” Toxicology Letters 307 (2019): 41–48.

[319] J. Xu, Z. Zhang, H. Hu, et al., “Synergistic Antitumor Effects of Peiminine and Doxorubicin on Breast Cancer Through Enhancing DNA Damage via ZEB1,” Biomedicine & Pharmacotherapy 173 (2024): 116353.

[320] L. Wang, R. Luo, K. Onyshchenko, et al., “Adding Liposomal Doxorubicin Enhances the Abscopal Effect Induced by Radiation/αPD1 Therapy Depending on Tumor Cell Mitochondrial DNA and cGAS/STING,” Journal for Immunotherapy of Cancer 11, no. 8 (2023): e006235.

[321] Y. Zou, Y. Wang, S. Xu, et al., “Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy,” Advanced Materials 34, no. 33 (2022): e2203958.

[322] A. P. West, W. Khoury-Hanold, M. Staron, et al., “Mitochondrial DNA Stress Primes the Antiviral Innate Immune Response,” Nature 520, no. 7548 (2015): 553–557.

[323] E. J. Jordan, H. R. Kim, M. E. Arcila, et al., “Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies,” Cancer Discovery 7, no. 6 (2017): 596–609.

[324] P. Bailey, D. K. Chang, K. Nones, et al., “Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer,” Nature 531, no. 7592 (2016): 47–52.

[325] S. Dhillon, “Adagrasib: First Approval,” Drugs 83, no. 3 (2023): 275–285.

[326] J. Zhang, S. M. Lim, M. R. Yu, et al., “D3S-001, a KRAS G12C Inhibitor With Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities,” Cancer Discovery 14, no. 9 (2024): 1675–1698.

[327] J. Zhou, J. Luo, P. Li, et al., “Triptolide Promotes Degradation of the Unfolded Gain-of-Function Tp53(R175H/Y220C) Mutant Protein by Initiating Heat Shock Protein 70 Transcription in Non-Small Cell Lung Cancer,” Translational Lung Cancer Research 11, no. 5 (2022): 802–816.

[328] N. Mohell, J. Alfredsson, Å. Fransson, et al., “APR-246 Overcomes Resistance to Cisplatin and Doxorubicin in Ovarian Cancer Cells,” Cell Death & Disease 6, no. 6 (2015): e1794.

[329] S. Gomes, B. Bosco, J. B. Loureiro, et al., “SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 Through Hsp70: Promising Activity in Hepatocellular Carcinoma,” Cancers 11, no. 8 (2019): 1151.

[330] Q. Liu, J. He, X. Zhou, et al., “ACP-5862 Suppresses Esophageal Squamous Cell Carcinoma Growth Through Inducing Apoptosis via Activation of Endoplasmic Reticulum Stress and ROS Production,” Biochemical and Biophysical Research Communications 534 (2021): 995–1002.

[331] Y. Du, L. Lei, H. Ding, et al., “Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase,” Frontiers in Immunology 13 (2022): 893899.

[332] C. G. Peace and L. A. J. O'Neill, “The Role of Itaconate in Host Defense and Inflammation,” Journal of Clinical Investigation 132, no. 2 (2022): e148548.

[333] M. Galasso, S. Gambino, M. G. Romanelli, M. Donadelli, and M. T. Scupoli, “Browsing the Oldest Antioxidant Enzyme: Catalase and its Multiple Regulation in Cancer,” Free Radical Biology and Medicine 172 (2021): 264–272.

[334] S. Heo, S. Kim, and D. Kang, “The Role of Hydrogen Peroxide and Peroxiredoxins Throughout the Cell Cycle,” Antioxidants 9, no. 4 (2020): 280.

[335] R. Margis, C. Dunand, F. K. Teixeira, and M. Margis-Pinheiro, “Glutathione Peroxidase Family—An Evolutionary Overview,” FEBS Journal 275, no. 15 (2008): 3959–3970.

[336] Y. Wang, R. Branicky, A. Noë, and S. Hekimi, “Superoxide Dismutases: Dual Roles in Controlling ROS Damage and Regulating ROS Signaling,” Journal of Cell Biology 217, no. 6 (2018): 1915–1928.

[337] S. M. Beer, E. R. Taylor, S. E. Brown, et al., “Glutaredoxin 2 Catalyzes the Reversible Oxidation and Glutathionylation of Mitochondrial Membrane Thiol Proteins,” Journal of Biological Chemistry 279, no. 46 (2004): 47939–47951.

[338] B. L. Kedrowski, J. H. Gutow, G. Stock, M. Smith, C. Jordan, and D. S. Masterson, “Glutathione Reductase Activity With an Oxidized Methylated Glutathione Analog,” Journal of Enzyme Inhibition and Medicinal Chemistry 29, no. 4 (2014): 491–494.

[339] G. R. M. M. Haenen and A. Bast, “Glutathione Revisited: A Better Scavenger Than Previously Thought,” Frontiers in Pharmacology 5 (2014): 260.

[340] S. J. Hwang, Y. W. Kim, Y. Park, H. J. Lee, and K. W. Kim, “Anti-Inflammatory Effects of Chlorogenic Acid in Lipopolysaccharide-Stimulated Raw 264.7 Cells,” Inflammation Research 63, no. 1 (2014): 81–90.

[341] S. Guo, K. Jiang, H. Wu, et al., “Magnoflorine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Suppressing NF-κB and MAPK Activation,” Frontiers in Pharmacology 9 (2018): 982.

[342] M. Hashemzaei and R. Rezaee, “A Review on Pain-Relieving Activity of Berberine,” Phytotherapy Research 35, no. 6 (2021): 2846–2853.

[343] X. Li, Y. Bai, Y. Ma, and Y. Li, “Ameliorating Effects of Berberine on Sepsis-Associated Lung Inflammation Induced by Lipopolysaccharide: Molecular Mechanisms and Preclinical Evidence,” Pharmacological Reports 75, no. 4 (2023): 805–816.

[344] Y. Yan, L. Wang, S. Chen, et al., “Carbon Monoxide Inhibits T Cell Proliferation by Suppressing Reactive Oxygen Species Signaling,” Antioxidants & Redox Signaling 32, no. 7 (2020): 429–446.

[345] T. L. Nguyen, Y. Choi, J. Im, et al., “Immunosuppressive Biomaterial-Based Therapeutic Vaccine to Treat Multiple Sclerosis via Re-Establishing Immune Tolerance,” Nature Communications 13, no. 1 (2022): 7449.

[346] J. Zhou, W. Liu, X. Zhao, et al., “Natural Melanin/Alginate Hydrogels Achieve Cardiac Repair Through ROS Scavenging and Macrophage Polarization,” Advanced Science 8, no. 20 (2021): e2100505.

[347] Y. Xia, J. Chen, Y. Yu, et al., “Compensatory Combination of mTOR and TrxR Inhibitors to Cause Oxidative Stress and Regression of Tumors,” Theranostics 11, no. 9 (2021): 4335–4350.

[348] E. J. Han, E. Y. Choi, S. J. Jeon, et al., “Piperlongumine Induces Apoptosis and Autophagy via the PI3K/Akt/mTOR Pathway in KB Human Cervical Cancer Cells,” Food and Chemical Toxicology 180 (2023): 114051.

[349] S. Jiang, T. Li, X. Zhou, W. Qin, Z. Wang, and Y. Liao, “Antibiotic Drug Piperacillin Induces Neuron Cell Death Through Mitochondrial Dysfunction and Oxidative Damage,” Canadian Journal of Physiology and Pharmacology 96, no. 6 (2018): 562–568.

[350] Q. Yao, Y. Tang, S. Dai, et al., “A Biomimetic Nanoparticle Exerting Protection Against Acute Liver Failure by Suppressing CYP2E1 Activity and Scavenging Excessive ROS,” Advanced Healthcare Materials 12, no. 24 (2023): e2300571.

[351] X. Liu, H. Suo, S. Zhou, et al., “Afatinib Induces Pro-Survival Autophagy and Increases Sensitivity to Apoptosis in Stem-Like HNSCC Cells,” Cell Death & Disease 12, no. 8 (2021): 728.

[352] A. A. Elzagallaai, E. A. Sultan, J. R. Bend, A. M. Abuzgaia, E. Loubani, and M. J. Rieder, “Role of Oxidative Stress Hypersensitivity Reactions to Sulfonamides,” Journal of Clinical Pharmacology 60, no. 3 (2020): 409–421.

[353] R. Ghosh, A. Alajbegovic, and A. V. Gomes, “NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species,” Oxidative Medicine and Cellular Longevity 2015 (2015): 536962.

[354] S. Ma, E. S. Henson, Y. Chen, and S. B. Gibson, “Ferroptosis Is Induced Following Siramesine and Lapatinib Treatment of Breast Cancer Cells,” Cell Death & Disease 7, no. 7 (2016): e2307.

[355] Z. Zhou, J. Chen, Y. Liu, et al., “Cascade Two-Stage Tumor Re-Oxygenation and Immune Re-Sensitization Mediated by Self-Assembled Albumin-Sorafenib Nanoparticles for Enhanced Photodynamic Immunotherapy,” Acta Pharmaceutica Sinica B 12, no. 11 (2022): 4204–4223.

[356] R. Su, G. Chong, H. Dong, et al., “Nanovaccine Biomineralization for Cancer Immunotherapy: a NADPH Oxidase-Inspired Strategy for Improving Antigen Cross-Presentation via Lipid Peroxidation,” Biomaterials 277 (2021): 121089.

[357] E. Yuba, A. Yamaguchi, Y. Yoshizaki, A. Harada, and K. Kono, “Bioactive Polysaccharide-Based pH-Sensitive Polymers for Cytoplasmic Delivery of Antigen and Activation of Antigen-Specific Immunity,” Biomaterials 120 (2017): 32–45.

[358] X. Liang, X. Li, J. Duan, et al., “Nanoparticles With CD44 Targeting and ROS Triggering Properties as Effective In Vivo Antigen Delivery System,” Molecular Pharmaceutics 15, no. 2 (2018): 508–518.

[359] W. Chen, W. Yan, and L. Huang, “A Simple but Effective Cancer Vaccine Consisting of an Antigen and a Cationic Lipid,” Cancer Immunology, Immunotherapy 57, no. 4 (2008): 517–530.

[360] H. Wang, K. Wang, L. He, Y. Liu, H. Dong, and Y. Li, “Engineering Antigen as Photosensitiser Nanocarrier to Facilitate ROS Triggered Immune Cascade for Photodynamic Immunotherapy,” Biomaterials 244 (2020): 119964.

[361] E. L. Mills, D. G. Ryan, H. A. Prag, et al., “Itaconate Is an Anti-Inflammatory Metabolite That Activates Nrf2 via Alkylation of KEAP1,” Nature 556, no. 7699 (2018): 113–117.

[362] A. Hooftman and L. A. J. O'Neill, “The Immunomodulatory Potential of the Metabolite Itaconate,” Trends in Immunology 40, no. 8 (2019): 687–698.

[363] S. T. Liao, C. Han, D. Q. Xu, X. W. Fu, J. S. Wang, and L. Y. Kong, “4-Octyl Itaconate Inhibits Aerobic Glycolysis by Targeting GAPDH to Exert Anti-Inflammatory Effects,” Nature Communications 10, no. 1 (2019): 5091.

[364] M. C. Runtsch, S. Angiari, A. Hooftman, et al., “Itaconate and Itaconate Derivatives Target JAK1 to Suppress Alternative Activation of Macrophages,” Cell Metabolism 34, no. 3 (2022): 487–501.

[365] M. M. Blewett, J. Xie, B. W. Zaro, et al., “Chemical Proteomic Map of Dimethyl Fumarate-Sensitive Cysteines in Primary Human T Cells,” Science Signaling 9, no. 445 (2016): rs10.

[366] N. Salame, J. P. Bikorimana, N. El-Hachem, et al., “UM171A-induced ROS Promote Antigen Cross-Presentation of Immunogenic Peptides by Bone Marrow-Derived Mesenchymal Stromal Cells,” Stem Cell Research & Therapy 13, no. 1 (2022): 16.

[367] A. Nadeem, S. F. Ahmad, N. O. Al-Harbi, et al., “Bruton's Tyrosine Kinase Inhibition Attenuates Oxidative Stress in Systemic Immune Cells and Renal Compartment During Sepsis-Induced Acute Kidney Injury in Mice,” International Immunopharmacology 90 (2021): 107123.

[368] E. Bame, H. Tang, J. C. Burns, et al., “Next-Generation Bruton's Tyrosine Kinase Inhibitor BIIB091 Selectively and Potently Inhibits B Cell and Fc Receptor Signaling and Downstream Functions in B Cells and Myeloid Cells,” Clinical & Translational Immunology 10, no. 6 (2021): e1295.

[369] S. Dhillon, “Tirabrutinib: First Approval,” Drugs 80, no. 8 (2020): 835–840.

[370] Y. Guo, N. Hu, Y. Liu, et al., “Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases,” Journal of Medicinal Chemistry 66, no. 6 (2023): 4025–4044.

[371] S. H. Watterson, Q. Liu, M. Beaudoin Bertrand, et al., “Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid In Vivo Inactivation of Bruton's Tyrosine Kinase (BTK),” Journal of Medicinal Chemistry 62, no. 7 (2019): 3228–3250.

[372] D. Angst, F. Gessier, P. Janser, et al., “Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase,” Journal of Medicinal Chemistry 63, no. 10 (2020): 5102–5118.

[373] J. J. Crawford, A. R. Johnson, D. L. Misner, et al., “Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development,” Journal of Medicinal Chemistry 61, no. 6 (2018): 2227–2245.

[374] J. Jia, Y. Zhang, Y. Xin, C. Jiang, B. Yan, and S. Zhai, “Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy,” Frontiers in Oncology 8 (2018): 404.

[375] C. Wang, P. Li, L. Liu, et al., “Self-Adjuvanted Nanovaccine for Cancer Immunotherapy: Role of Lysosomal Rupture-Induced ROS in MHC Class I Antigen Presentation,” Biomaterials 79 (2016): 88–100.

[376] W. Yan, W. Chen, and L. Huang, “Reactive Oxygen Species Play a Central Role in the Activity of Cationic Liposome Based Cancer Vaccine,” Journal of Controlled Release 130, no. 1 (2008): 22–28.

[377] G. Yang, L. Xu, Y. Chao, et al., “Hollow MnO(2) as a Tumor-Microenvironment-Responsive Biodegradable Nano-Platform for Combination Therapy Favoring Antitumor Immune Responses,” Nature Communications 8, no. 1 (2017): 902.

[378] Y. Xiong, C. Xiao, Z. Li, and X. Yang, “Engineering Nanomedicine for Glutathione Depletion-Augmented Cancer Therapy,” Chemical Society Reviews 50, no. 10 (2021): 6013–6041.

[379] S. Chen, Y. Lv, Y. Wang, et al., “Tumor Acidic Microenvironment-Responsive Promodulator Iron Oxide Nanoparticles for Photothermal-Enhanced Chemodynamic Immunotherapy of Cancer,” ACS Biomaterials Science & Engineering 9, no. 2 (2023): 773–783.

[380] H. Xiao, X. Li, B. Li, et al., “Nanodrug Inducing Autophagy Inhibition and Mitochondria Dysfunction for Potentiating Tumor Photo-Immunotherapy,” Small 19, no. 30 (2023): e2300280.

[381] D. Mao, F. Hu, Z. Yi, et al., “Aiegen-Coupled Upconversion Nanoparticles Eradicate Solid Tumors Through Dual-Mode ROS Activation,” Science Advances 6, no. 26 (2020): eabb2712.

[382] Z. Yang, Y. Teng, M. Lin, et al., “Reinforced Immunogenic Endoplasmic Reticulum Stress and Oxidative Stress via an Orchestrated Nanophotoinducer to Boost Cancer Photoimmunotherapy,” ACS Nano 18, no. 9 (2024): 7267–7286.

[383] C. Yang, Y. Luo, H. Shen, et al., “Inorganic Nanosheets Facilitate Humoral Immunity Against Medical Implant Infections by Modulating Immune Co-Stimulatory Pathways,” Nature Communications 13, no. 1 (2022): 4866.

[384] C. Shi, J. Zhang, H. Wang, et al., “Trojan Horse Nanocapsule Enabled In Situ Modulation of the Phenotypic Conversion of Th17 Cells to Treg Cells for the Treatment of Multiple Sclerosis in Mice,” Advanced Materials 35, no. 11 (2023): e2210262.

[385] Z. Tang, S. Meng, X. Yang, et al., “Neutrophil-Mimetic, ROS Responsive, and Oxygen Generating Nanovesicles for Targeted Interventions of Refractory Rheumatoid Arthritis,” Small 20, no. 20 (2024): e2307379.

[386] G. Chen, S. Deng, S. Liu, et al., “pH and ROS Dual-Sensitive Nanocarriers for the Targeted Co-Delivery and On-Demand Sequential Release of Tofacitinib and Glucosamine for Synergistic Rheumatoid Arthritis Treatment,” Small 20, no. 24 (2024): e2308520.

[387] M. L. Soriano Pérez, J. A. Funes, C. Flores Bracamonte, et al., “Development and Biological Evaluation of pNIPAM-Based Nanogels as Vaccine Carriers,” International Journal of Pharmaceutics 630 (2023): 122435.

[388] N. M. Phan, T. L. Nguyen, H. Shin, T. A. Trinh, and J. Kim, “ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis,” ACS Nano 17, no. 24 (2023): 24696–24709.

[389] I. Melero, E. Castanon, M. Alvarez, S. Champiat, and A. Marabelle, “Intratumoural Administration and Tumour Tissue Targeting of Cancer Immunotherapies,” Nature Reviews Clinical Oncology 18, no. 9 (2021): 558–576.

[390] L. Lyu, Y. Feng, X. Chen, and Y. Hu, “The Global Chimeric Antigen Receptor T (CAR-T) Cell Therapy Patent Landscape,” Nature Biotechnology 38, no. 12 (2020): 1387–1394.

[391] N. B. Nagarsheth, S. M. Norberg, A. L. Sinkoe, et al., “TCR-Engineered T Cells Targeting E7 for Patients With Metastatic HPV-Associated Epithelial Cancers,” Nature Medicine 27, no. 3 (2021): 419–425.

[392] W. Scheper, S. Kelderman, L. F. Fanchi, et al., “Low and Variable Tumor Reactivity of the Intratumoral TCR Repertoire in Human Cancers,” Nature Medicine 25, no. 1 (2019): 89–94.

[393] J. Galon, A. Costes, F. Sanchez-Cabo, et al., “Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome,” Science 313, no. 5795 (2006): 1960–1964.

[394] L. Zhang, J. R. Conejo-Garcia, D. Katsaros, et al., “Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer,” New England Journal of Medicine 348, no. 3 (2003): 203–213.

[395] P. Kesarwani, P. Chakraborty, R. Gudi, et al., “Blocking TCR Restimulation Induced Necroptosis in Adoptively Transferred T Cells Improves Tumor Control,” Oncotarget 7, no. 43 (2016): 69371–69383.

[396] E. Balta, N. Janzen, H. Kirchgessner, et al., “Expression of TRX1 Optimizes the Antitumor Functions of Human CAR T Cells and Confers Resistance to a Pro-Oxidative Tumor Microenvironment,” Frontiers in Immunology 13 (2022): 1063313.

[397] A. Matsuzawa, “Thioredoxin and Redox Signaling: Roles of the Thioredoxin System in Control of Cell Fate,” Archives of Biochemistry and Biophysics 617 (2017): 101–105.

[398] S. H. Jackson, S. Devadas, J. Kwon, L. A. Pinto, and M. S. Williams, “T Cells Express a Phagocyte-Type NADPH Oxidase That Is Activated After T Cell Receptor Stimulation,” Nature Immunology 5, no. 8 (2004): 818–827.

[399] J. N. Rashida Gnanaprakasam, R. Wu, and R. Wang, “Metabolic Reprogramming in Modulating T Cell Reactive Oxygen Species Generation and Antioxidant Capacity,” Frontiers in Immunology 9 (2018): 1075.

[400] S. D. Crowley, “The Cooperative Roles of Inflammation and Oxidative Stress in the Pathogenesis of Hypertension,” Antioxidants & Redox Signaling 20, no. 1 (2014): 102–120.

[401] J. B. Lee, D. H. Khan, R. Hurren, et al., “Venetoclax Enhances T Cell-Mediated Antileukemic Activity by Increasing ROS Production,” Blood 138, no. 3 (2021): 234–245.

[402] L. Xianchu, Z. Lan, L. Ming, and M. Yanzhi, “Protective Effects of Rutin on Lipopolysaccharide-Induced Heart Injury in Mice,” Journal of Toxicological Sciences 43, no. 5 (2018): 329–337.

[403] A. Sharma, N. V. Tirpude, N. Bhardwaj, D. Kumar, and Y. Padwad, “Berberis Lycium Fruit Extract and Its Phytoconstituents Berberine and Rutin Mitigate Collagen-Cfa-Induced Arthritis (CIA) via Improving GSK3β/STAT/Akt/MAPKs/NF-κB Signaling Axis Mediated Oxi-Inflammation and Joint Articular Damage in Murine Model,” Inflammopharmacology 30, no. 2 (2022): 655–666.

[404] S. W. Ryter, “Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders,” Antioxidants 11, no. 3 (2022): 555.

[405] A. Sharma, R. Sharma, D. Kumar, and Y. Padwad, “Berberis Lycium Royle Fruit Extract Mitigates Oxi-Inflammatory Stress by Suppressing NF-κB/MAPK Signalling Cascade in Activated Macrophages and Treg Proliferation in Splenic Lymphocytes,” Inflammopharmacology 28, no. 4 (2020): 1053–1072.

[406] Y. Wang, C. Li, Y. Wan, et al., “Quercetin-Loaded Ceria Nanocomposite Potentiate Dual-Directional Immunoregulation via Macrophage Polarization Against Periodontal Inflammation,” Small 17, no. 41 (2021): e2101505.

[407] Y. Sun, X. Sun, X. Li, et al., “A Versatile Nanocomposite Based on Nanoceria for Antibacterial Enhancement and Protection From aPDT-Aggravated Inflammation via Modulation of Macrophage Polarization,” Biomaterials 268 (2021): 120614.

[408] N. Tran and E. L. Mills, “Redox Regulation of Macrophages,” Redox Biology 72 (2024): 103123.

[409] Y. Zhou, K. T. Que, Z. Zhang, et al., “Iron Overloaded Polarizes Macrophage to Proinflammation Phenotype Through ROS/acetyl-p53 Pathway,” Cancer Medicine 7, no. 8 (2018): 4012–4022.

[410] S. Fang, S. Sun, H. Cai, et al., “IRGM/Irgm1 Facilitates Macrophage Apoptosis Through ROS Generation and MAPK Signal Transduction: Irgm1(+/−) Mice Display Increases Atherosclerotic Plaque Stability,” Theranostics 11, no. 19 (2021): 9358–9375.

[411] Z. Luo, Z. Sheng, L. Hu, et al., “Targeted Macrophage Phagocytosis by Irg1/itaconate Axis Improves the Prognosis of Intracerebral Hemorrhagic Stroke and Peritonitis,” EBioMedicine 101 (2024): 104993.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).